

(19) World Intellectual Property Organization
International Bureau(43) International Publication Date
27 December 2001 (27.12.2001)

PCT

(10) International Publication Number
WO 01/98272 A1(51) International Patent Classification⁷: C07D 211/46,
211/58, 211/22, 207/12, 295/08, 295/10, A61K 31/295SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA,
ZW.

(21) International Application Number: PCT/SE01/01378

(84) Designated States (regional): ARIPO patent (GH, GM,
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian
patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European
patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE,
IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF,
CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

(22) International Filing Date: 14 June 2001 (14.06.2001)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:

0002330-9 20 June 2000 (20.06.2000) SE
0003980-0 31 October 2000 (31.10.2000) SE(71) Applicant (for all designated States except US): AS-
TRAZENECA AB [SE/SE]; S-151 85 Södertälje (SE).

(72) Inventors; and

(75) Inventors/Applicants (for US only): ERIKSSON, Tomas
[SE/SE]; AstraZeneca R & D Lund, S-221 87 Lund (SE).
HENRIKSSON, Krister [SE/SE]; AstraZeneca R & D
Lund, S-221 87 Lund (SE).(74) Agent: GLOBAL INTELLECTUAL PROPERTY; As-
traZeneca AB, S-151 85 Södertälje (SE).(81) Designated States (national): AE, AG, AL, AM, AT, AU,
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU,
CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW,
MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK,

Declarations under Rule 4.17:


- as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii)) for the following designations AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG)
- of inventorship (Rule 4.17(iv)) for US only

Published:

- with international search report
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: NOVEL COMPOUNDS



(I)

(57) Abstract: The invention provides compounds of general formula (I) wherein m, n, Z¹, Z², R¹, R², R³, R⁴, R⁵, R⁶, R⁷ and R⁸ are as defined in the specification, process for their preparation, pharmaceutical compositions containing them and their use in therapy.

NOVEL COMPOUNDS

The present invention relates to novel compounds, processes for their preparation, pharmaceutical compositions containing them and their use in therapy.

5


Chemokines play an important role in immune and inflammatory responses in various diseases and disorders, including asthma and allergic diseases, as well as autoimmune pathologies such as rheumatoid arthritis and atherosclerosis. These small secreted molecules are a growing superfamily of 8-14 kDa proteins characterised by a conserved
10 four cysteine motif. The chemokine superfamily can be divided into two main groups exhibiting characteristic structural motifs, the Cys-X-Cys (C-X-C) and Cys-Cys (C-C) families. These are distinguished on the basis of a single amino acid insertion between the NH-proximal pair of cysteine residues and sequence similarity.

15 The C-X-C chemokines include several potent chemoattractants and activators of neutrophils such as interleukin-8 (IL-8) and neutrophil-activating peptide 2 (NAP-2).

The C-C chemokines include potent chemoattractants of monocytes and lymphocytes but not neutrophils such as human monocyte chemotactic proteins 1-3 (MCP-1, MCP-2 and
20 MCP-3), RANTES (Regulated on Activation, Normal T Expressed and Secreted), eotaxin and the macrophage inflammatory proteins 1 α and 1 β (MIP-1 α and MIP-1 β).

Studies have demonstrated that the actions of the chemokines are mediated by subfamilies of G protein-coupled receptors, among which are the receptors designated CCR1, CCR2,
25 CCR2A, CCR2B, CCR3, CCR4, CCR5, CCR6, CCR7, CCR8, CCR9, CCR10, CXCR1, CXCR2, CXCR3 and CXCR4. These receptors represent good targets for drug development since agents which modulate these receptors would be useful in the treatment of disorders and diseases such as those mentioned above.

In accordance with the present invention, there is therefore provided a compound of general formula



5 wherein:

m is 0, 1, 2 or 3;

each R¹ independently represents halogen, cyano, nitro, carboxyl, hydroxyl, C₃-C₆ cycloalkyl, C₁-C₆ alkoxy, C₁-C₆ alkoxy carbonyl, C₁-C₆ haloalkyl, C₁-C₆ haloalkoxy, -NR⁹R¹⁰, C₃-C₆ cycloalkylamino, C₁-C₆ alkylthio, 10 C₁-C₆ alkylcarbonyl, C₁-C₆ alkylcarbonylamino, sulphonamido (-SO₂NH₂), C₁-C₆ alkylsulphonyl, -C(O)NR¹¹R¹², -NR¹³C(O)-(NH)_pR¹⁴, phenyl, or C₁-C₆ alkyl optionally substituted by carboxyl or C₁-C₆ alkoxy carbonyl;

p is 0 or 1;


X represents an oxygen atom or a CH₂, OCH₂, CH₂O, CH₂NH, NH, carbonyl or 15 sulphonyl group and Y represents a nitrogen atom or a CH or C(OH) group, provided that when X represents an oxygen atom or a CH₂O, CH₂NH or NH group, then Y represents a CH group;

Z¹ represents a bond or a group (CH₂)_q where q is 1 or 2;

Z² represents a bond or a group CH₂, with the proviso that Z¹ and Z² do not both 20 simultaneously represent a bond;

Q represents an oxygen or sulphur atom or a group CH₂ or NH;

R² represents a group



n is 0, 1 or 2;

each R³ independently represents a C₁-C₆ alkyl, C₁-C₆ alkoxycarbonyl, -CH₂OH or carboxyl group;

R⁴, R⁵, R⁶ and R⁷ each independently represent a hydrogen atom or a C₁-C₆ alkyl group, or R⁴, R⁵, R⁶ and R⁷ together represent a C₁-C₄ alkylene chain linking the two carbon atoms to which they are attached to form a 4- to 7-membered saturated carbocycle, or R⁵, R⁶ and R⁷ each represent a hydrogen atom and R⁴ and R⁸ together with the carbon atoms to which they are attached form a 5- to 6-membered saturated carbocycle;

R⁸ represents a hydrogen atom, a C₁-C₆ alkyl group or is linked to R⁴ as defined above;

R⁹ and R¹⁰ each independently represent a hydrogen atom or a C₁-C₆ alkyl group, or R⁹ and R¹⁰ together with the nitrogen atom to which they are attached form a 4- to 7-membered saturated heterocycle;

R¹¹ and R¹² each independently represent a hydrogen atom or a C₁-C₆ alkyl group optionally substituted by C₁-C₆ alkoxycarbonyl;

R¹³ represents a hydrogen atom or a C₁-C₆ alkyl group;

R¹⁴ represents a hydrogen atom, or a C₁-C₆ alkyl group optionally substituted by carboxyl, C₁-C₆ alkoxy or C₁-C₆ alkoxycarbonyl;

R¹⁵ represents a group C₂-C₆ alkyl, C₂-C₆ alkenyl, C₃-C₆ cycloalkyl, C₅-C₆ cycloalkenyl, adamantyl, phenyl or a saturated or unsaturated 5- to 10-membered heterocyclic ring system comprising at least one heteroatom selected from nitrogen, oxygen and sulphur, wherein each group may be optionally substituted by one or more substituents independently selected from nitro, hydroxyl, oxo, halogen, carboxyl, C₁-C₆ alkyl, C₁-C₆ alkoxy, C₁-C₆ alkylthio, C₁-C₆ alkylcarbonyl, C₁-C₆ alkoxycarbonyl, phenyl and -NHC(O)-R¹⁷, with the proviso that R¹⁵ does not represent an unsubstituted 1-pyrrolidinyl, an unsubstituted 1-piperidinyl or an unsubstituted 1-hexamethyleneiminyl (1-homopiperidinyl) group;

t is 0, 1, 2 or 3;

each R¹⁶ independently represents halogen, cyano, nitro, carboxyl, hydroxyl, C₃-C₆ cycloalkyl, C₁-C₆ alkoxy, C₁-C₆ alkoxycarbonyl, C₁-C₆ haloalkyl,

C₁-C₆ haloalkoxy, -NR¹⁸R¹⁹, C₃-C₆ cycloalkylamino, C₁-C₆ alkylthio, C₁-C₆ alkylcarbonyl, C₁-C₆ alkylcarbonylamino, sulphonamido (-SO₂NH₂), C₁-C₆ alkylsulphonyl, -C(O)NR²⁰R²¹, -NR²²C(O)(NH)_vR²³, phenyl, or C₁-C₆ alkyl optionally substituted by carboxyl or C₁-C₆ alkoxy carbonyl;

5 R¹⁷ represents a C₁-C₆ alkyl, amino (-NH₂) or phenyl group;

R¹⁸ and R¹⁹ each independently represent a hydrogen atom or a C₁-C₆ alkyl group, or R¹⁸ and R¹⁹ together with the nitrogen atom to which they are attached form a 4- to 7-membered saturated heterocycle;

R²⁰ and R²¹ each independently represent a hydrogen atom or a C₁-C₆ alkyl group
10 optionally substituted by C₁-C₆ alkoxy carbonyl;

v is 0 or 1;

R²² represents a hydrogen atom or a C₁-C₆ alkyl group; and

R²³ represents a hydrogen atom, or a C₁-C₆ alkyl group optionally substituted by carboxyl, C₁-C₆ alkoxy or C₁-C₆ alkoxy carbonyl;

15 or a pharmaceutically acceptable salt or solvate thereof.

In the context of the present specification, an alkyl or alkenyl substituent group or an alkyl or alkenyl moiety in a substituent group may be linear or branched. In the definition of R¹⁵, it should be noted that the unsaturated 5- to 10-membered heterocyclic ring system
20 may be aliphatic or aromatic.

The integer m is preferably 1 or 2.

Each R¹ independently represents halogen (e.g. chlorine, fluorine, bromine or iodine),
25 cyano, nitro, carboxyl, hydroxyl, C₃-C₆ cycloalkyl (cyclopropyl, cyclobutyl, cyclopentyl or cyclohexyl), C₁-C₆, preferably C₁-C₄, alkoxy (e.g. methoxy, ethoxy, n-propoxy or n-butoxy), C₁-C₆, preferably C₁-C₄, alkoxy carbonyl (e.g. methoxycarbonyl or ethoxycarbonyl), C₁-C₆, preferably C₁-C₄, haloalkyl (e.g. trifluoromethyl), C₁-C₆, preferably C₁-C₄, haloalkoxy (e.g. trifluoromethoxy), -NR⁹R¹⁰,
30 C₃-C₆ cycloalkylamino (e.g. cyclopropylamino, cyclobutylamino, cyclopentylamino or

cyclohexylamino), C₁-C₆, preferably C₁-C₄, alkylthio (e.g. methylthio or ethylthio), C₁-C₆, preferably C₁-C₄, alkylcarbonyl (e.g. methylcarbonyl, ethylcarbonyl, n-propylcarbonyl, isopropylcarbonyl, n-butylcarbonyl, n-pentylcarbonyl or n-hexylcarbonyl), C₁-C₆, preferably C₁-C₄, alkylcarbonylamino (e.g. methylcarbonylamino or ethylcarbonylamino), sulphonamido, C₁-C₆, preferably C₁-C₄, alkylsulphonyl (e.g. methylsulphonyl, ethylsulphonyl, n-propylsulphonyl, isopropylsulphonyl, n-butylsulphonyl, n-pentylsulphonyl or n-hexylsulphonyl), -C(O)NR¹¹R¹², -NR¹³C(O)-(NH)_pR¹⁴, phenyl, or C₁-C₆, preferably C₁-C₄, alkyl (e.g. methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, tert-butyl, n-pentyl or n-hexyl) optionally substituted by carboxyl or C₁-C₆, preferably C₁-C₄, alkoxycarbonyl (e.g. methoxycarbonyl or ethoxycarbonyl).

Most preferably, each R¹ independently represents halogen (particularly chlorine or fluorine), cyano, nitro, C₁-C₆ alkoxy (especially methoxy), C₁-C₆ alkylcarbonyl (especially methylcarbonyl) or C₁-C₆ alkylcarbonylamino (particularly methylcarbonylamino). Each R¹ especially represents halogen or cyano.

Preferably X represents an oxygen atom or a CH₂ or NH group.

Preferred combinations of Y, Z¹ and Z² include:

Y	Z ¹	Z ²
CH	CH ₂	bond
CH	bond	CH ₂
CH	CH ₂	CH ₂
CH	(CH ₂) ₂	bond
N	CH ₂	CH ₂

Q preferably represents an oxygen atom.

Each R^3 independently represents a C_1 - C_6 , preferably C_1 - C_4 , alkyl (e.g. methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, tert-butyl, n-pentyl or n-hexyl), C_1 - C_6 , preferably C_1 - C_4 , alkoxy carbonyl (e.g. methoxy carbonyl or ethoxy carbonyl), $-CH_2OH$ or carboxyl group. It is preferred that R^3 represents a methyl, methoxy carbonyl, ethoxy carbonyl, $-CH_2OH$ or carboxyl group.

R^4 , R^5 , R^6 and R^7 each independently represent a hydrogen atom or a C_1 - C_6 , preferably C_1 - C_4 , alkyl (e.g. methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, tert-butyl, n-pentyl or n-hexyl), or R^4 , R^5 , R^6 and R^7 together represent a C_1 - C_4 alkylene chain linking the two carbon atoms to which they are attached to form a 4- to 7-membered saturated carbocycle (e.g. cyclohexyl or preferably cyclopentyl), or R^5 , R^6 and R^7 each represent a hydrogen atom and R^4 and R^8 together with the carbon atoms to which they are attached form a 5- to 6-membered saturated carbocycle (preferably cyclopentyl).

R^8 represents a hydrogen atom, a C_1 - C_6 , preferably C_1 - C_4 , alkyl group (e.g. methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, tert-butyl, n-pentyl or n-hexyl) or is linked to R^4 as defined above.

R^9 and R^{10} each independently represent a hydrogen atom or a C_1 - C_6 , preferably C_1 - C_4 , alkyl group (e.g. methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, tert-butyl, n-pentyl or n-hexyl), or R^9 and R^{10} together with the nitrogen atom to which they are attached form a 4- to 7-membered saturated heterocycle.

R^{11} and R^{12} each independently represent a hydrogen atom or a C_1 - C_6 , preferably C_1 - C_4 , alkyl group (e.g. methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, tert-butyl, n-pentyl or n-hexyl) optionally substituted by a C_1 - C_6 , preferably C_1 - C_4 , alkoxy carbonyl substituent group.

R^{13} represents a hydrogen atom or a C_1 - C_6 , preferably C_1 - C_4 , alkyl group (e.g. methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, tert-butyl, n-pentyl or n-hexyl).

R¹⁴ represents a hydrogen atom, or a C₁-C₆, preferably C₁-C₄, alkyl group (e.g. methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, tert-butyl, n-pentyl or n-hexyl) optionally substituted by carboxyl, C₁-C₆, preferably C₁-C₄, alkoxy or C₁-C₆, preferably C₁-C₄, alkoxycarbonyl.

R¹⁵ represents a group C₂-C₆, preferably C₂-C₄, alkyl group (e.g. ethyl, n-propyl, isopropyl, n-butyl, isobutyl, tert-butyl or n-pentyl), C₂-C₆, preferably C₂-C₄, alkenyl, C₃-C₆ cycloalkyl (e.g. cyclobutyl or cyclopentyl), C₅-C₆ cycloalkenyl, adamantyl, phenyl or a saturated or unsaturated 5- to 10-membered heterocyclic ring system comprising at least one heteroatom selected from nitrogen, oxygen and sulphur, wherein each group may be optionally substituted by one or more (e.g. one, two, three or four) substituents independently selected from nitro, hydroxyl, oxo, halogen (e.g. fluorine, chlorine, bromine or iodine), carboxyl, C₁-C₆, preferably C₁-C₄, alkyl (e.g. methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, tert-butyl, n-pentyl or n-hexyl), C₁-C₆, preferably C₁-C₄, alkoxy (e.g. methoxy, ethoxy, n-propoxy or n-butoxy), C₁-C₆, preferably C₁-C₄, alkylthio (e.g. methylthio or ethylthio), C₁-C₆, preferably C₁-C₄, alkylcarbonyl (e.g. methylcarbonyl, ethylcarbonyl, n-propylcarbonyl, isopropylcarbonyl, n-butylcarbonyl, n-pentylcarbonyl or n-hexylcarbonyl), C₁-C₆, preferably C₁-C₄, alkoxycarbonyl (e.g. methoxycarbonyl or ethoxycarbonyl), phenyl and -NHC(O)-R¹⁷.

The saturated or unsaturated 5- to 10-membered heterocyclic ring system may be monocyclic or polycyclic (e.g. bicyclic) and may comprise up to four heteroatoms independently selected from nitrogen, oxygen and sulphur. Examples of ring systems that may be used include pyrrolidinyl, piperidinyl, pyrazolyl, thiazolidinyl, thienyl, isoxazolyl, thiadiazolyl, pyrrolyl, furanyl, thiazolyl, indolyl, quinolinyl, benzimidazolyl, triazolyl, tetrazolyl and pyridinyl.

Each R¹⁶ independently represents halogen (e.g. chlorine, fluorine, bromine or iodine), cyano, nitro, carboxyl, hydroxyl, C₃-C₆ cycloalkyl (cyclopropyl, cyclobutyl, cyclopentyl

or cyclohexyl), C₁-C₆, preferably C₁-C₄, alkoxy (e.g. methoxy, ethoxy, n-propoxy or n-butoxy), C₁-C₆, preferably C₁-C₄, alkoxycarbonyl (e.g. methoxycarbonyl or ethoxycarbonyl), C₁-C₆, preferably C₁-C₄, haloalkyl (e.g. trifluoromethyl), C₁-C₆, preferably C₁-C₄, haloalkoxy (e.g. trifluoromethoxy), -NR¹⁸R¹⁹,
 5 C₃-C₆ cycloalkylamino (e.g. cyclopropylamino, cyclobutylamino, cyclopentylamino or cyclohexylamino), C₁-C₆, preferably C₁-C₄, alkylthio (e.g. methylthio or ethylthio), C₁-C₆, preferably C₁-C₄, alkylcarbonyl (e.g. methylcarbonyl, ethylcarbonyl, n-propylcarbonyl, isopropylcarbonyl, n-butylcarbonyl, n-pentylcarbonyl or n-hexylcarbonyl), C₁-C₆, preferably C₁-C₄, alkylcarbonylamino (e.g.
 10 methylcarbonylamino or ethylcarbonylamino), sulphonamido, C₁-C₆, preferably C₁-C₄, alkylsulphonyl (e.g. methylsulphonyl, ethylsulphonyl, n-propylsulphonyl, isopropylsulphonyl, n-butylsulphonyl, n-pentylsulphonyl or n-hexylsulphonyl), -C(O)NR²¹R²², -NR²³C(O)-(NH)_vR²⁴, phenyl, or C₁-C₆, preferably C₁-C₄, alkyl (e.g. methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl,
 15 tert-butyl, n-pentyl or n-hexyl) optionally substituted by carboxyl or C₁-C₆, preferably C₁-C₄, alkoxycarbonyl (e.g. methoxycarbonyl or ethoxycarbonyl).

Preferably, each R¹⁶ independently represents halogen (particularly chlorine or fluorine), cyano, C₁-C₄ alkoxy (especially methoxy), C₁-C₄ alkoxycarbonyl (especially
 20 methoxycarbonyl), C₁-C₄ haloalkyl (especially trifluoromethyl), C₁-C₄ alkylcarbonyl (particularly methylcarbonyl), phenyl or C₁-C₄ alkyl (e.g. methyl or tert-butyl). Each R¹⁶ is especially a halogen atom or methyl group.

R¹⁷ represents a C₁-C₆, preferably C₁-C₄, alkyl group (e.g. methyl, ethyl, n-propyl,
 25 isopropyl, n-butyl, isobutyl, tert-butyl, n-pentyl or n-hexyl), amino or phenyl group.

R¹⁸ and R¹⁹ each independently represent a hydrogen atom or a C₁-C₆, preferably C₁-C₄, alkyl group (e.g. methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, tert-butyl, n-pentyl or n-hexyl), or R¹⁹ and R²⁰ together with the nitrogen atom to which they are
 30 attached form a 4- to 7-membered saturated heterocycle.

R^{20} and R^{21} each independently represent a hydrogen atom or a C_1 - C_6 , preferably C_1 - C_4 , alkyl group (e.g. methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, tert-butyl, n-pentyl or n-hexyl) optionally substituted by a C_1 - C_6 , preferably C_1 - C_4 , alkoxycarbonyl
5 substituent group.

R^{22} represents a hydrogen atom or a C_1 - C_6 , preferably C_1 - C_4 , alkyl group (e.g. methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, tert-butyl, n-pentyl or n-hexyl).

10 R^{23} represents a hydrogen atom, or a C_1 - C_6 , preferably C_1 - C_4 , alkyl group (e.g. methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, tert-butyl, n-pentyl or n-hexyl) optionally substituted by carboxyl, C_1 - C_6 , preferably C_1 - C_4 , alkoxy or C_1 - C_6 , preferably C_1 - C_4 , alkoxycarbonyl.

15 Preferred compounds of the invention include:

N-(5-Chloro-2-{3-[3-(4-chloro-phenoxy)-pyrrolidin-1-yl]-2-hydroxy-propoxy}-phenyl)-isobutyramide,

Thiophene-2-carboxylic acid (2-{3-[3-(4-chloro-phenoxy)-pyrrolidin-1-yl]-2-hydroxy-propoxy}-phenyl)-amide,

20 *N*-[(2-{3-[3-(4-Chloro-phenoxy)-pyrrolidin-1-yl]-2-hydroxy-propoxy}-phenylcarbamoyl)-methyl]-benzamide,

Pyrazine-2-carboxylic acid (2-{3-[3-(4-chloro-phenoxy)-pyrrolidin-1-yl]-2-hydroxy-propoxy}-phenyl)-amide,

25 Cyclohexanecarboxylic acid (2-{3-[3-(4-chloro-phenoxy)-pyrrolidin-1-yl]-2-hydroxy-propoxy}-phenyl)-amide,

N-(2-{3-[3-(4-Chloro-phenoxy)-pyrrolidin-1-yl]-2-hydroxy-propoxy}-phenyl)-phthalamic acid methyl ester,

N-(2-{3-[3-(4-Chloro-phenoxy)-pyrrolidin-1-yl]-2-hydroxy-propoxy}-phenyl)-3-hydroxy-butyramide,

N-(2-{3-[3-(4-Chloro-phenoxy)-pyrrolidin-1-yl]-2-hydroxy-propoxy}-phenyl)-2-ureido-acetamide,

4-Acetylamino-N-(2-{3-[3-(4-chloro-phenoxy)-pyrrolidin-1-yl]-2-hydroxy-propoxy}-phenyl)-butyramide,

5 1-Acetyl-piperidine-4-carboxylic acid (2-{3-[3-(4-chloro-phenoxy)-pyrrolidin-1-yl]-2-hydroxy-propoxy}-phenyl)-amide,

N-(2-{3-[3-(4-Chloro-phenoxy)-pyrrolidin-1-yl]-2-hydroxy-propoxy}-phenyl)-3-methoxy-benzamide,

2-Acetylamino-N-(2-{3-[3-(4-chloro-phenoxy)-pyrrolidin-1-yl]-2-hydroxy-propoxy}-phenyl)-3-methyl-butyramide,

2-Acetylamino-N-(2-{3-[3-(4-chloro-phenoxy)-pyrrolidin-1-yl]-2-hydroxy-propoxy}-phenyl)-3-hydroxy-butyramide,

Adamantane-1-carboxylic acid (2-{3-[3-(4-chloro-phenoxy)-pyrrolidin-1-yl]-2-hydroxy-propoxy}-phenyl)-amide,

15 2-Acetylamino-N-(2-{3-[3-(4-chloro-phenoxy)-pyrrolidin-1-yl]-2-hydroxy-propoxy}-phenyl)-3-phenyl-propionamide,

N-(2-{3-[3-(4-Chloro-phenoxy)-pyrrolidin-1-yl]-2-hydroxy-propoxy}-phenyl)-2-methoxy-benzamide,

5-Methyl-thiophene-2-carboxylic acid (2-{3-[3-(4-chloro-phenoxy)-pyrrolidin-1-yl]-2-hydroxy-propoxy}-phenyl)-amide,

1-Acetyl-pyrrolidine-2-carboxylic acid (2-{3-[3-(4-chloro-phenoxy)-pyrrolidin-1-yl]-2-hydroxy-propoxy}-phenyl)-amide,

1,5-Dimethyl-1H-pyrazole-3-carboxylic acid (2-{3-[3-(4-chloro-phenoxy)-pyrrolidin-1-yl]-2-hydroxy-propoxy}-phenyl)-amide,

25 5-Oxo-pyrrolidine-2-carboxylic acid (2-{3-[3-(4-chloro-phenoxy)-pyrrolidin-1-yl]-2-hydroxy-propoxy}-phenyl)-amide,

1H-Indole-6-carboxylic acid (2-{3-[3-(4-chloro-phenoxy)-pyrrolidin-1-yl]-2-hydroxy-propoxy}-phenyl)-amide,

Cyclobutanecarboxylic acid (2-{3-[3-(4-chloro-phenoxy)-pyrrolidin-1-yl]-2-hydroxy-propoxy}-phenyl)-amide,

N-(2-{3-[3-(4-Chloro-phenoxy)-pyrrolidin-1-yl]-2-hydroxy-propoxy}-phenyl)-propionamide,

Pentanoic acid (2-{3-[3-(4-chloro-phenoxy)-pyrrolidin-1-yl]-2-hydroxy-propoxy}-phenyl)-amide,

5 Pent-4-enoic acid (2-{3-[3-(4-chloro-phenoxy)-pyrrolidin-1-yl]-2-hydroxy-propoxy}-phenyl)-amide,

Cyclopentanecarboxylic acid (2-{3-[3-(4-chloro-phenoxy)-pyrrolidin-1-yl]-2-hydroxy-propoxy}-phenyl)-amide,

10 Cyclopropanecarboxylic acid (2-{3-[3-(4-chloro-phenoxy)-pyrrolidin-1-yl]-2-hydroxy-propoxy}-phenyl)-amide,

N-(2-{3-[3-(4-Chloro-phenoxy)-pyrrolidin-1-yl]-2-hydroxy-propoxy}-phenyl)-isobutyramide,

N-(2-{3-[3-(4-Chloro-phenoxy)-pyrrolidin-1-yl]-2-hydroxy-propoxy}-phenyl)-2-methylsulfanyl-acetamide,

15 2-Acetyl-amino-N-(2-{3-[3-(4-chloro-phenoxy)-pyrrolidin-1-yl]-2-hydroxy-propoxy}-phenyl)-propionamide,

N-(2-{3-[3-(4-Chloro-phenoxy)-pyrrolidin-1-yl]-2-hydroxy-propoxy}-phenyl)-butyramide,

20 N-(2-{3-[3-(4-Chloro-phenoxy)-pyrrolidin-1-yl]-2-hydroxy-propoxy}-phenyl)-3-methyl-butylamide,

N-(2-{3-[3-(4-Chloro-phenoxy)-pyrrolidin-1-yl]-2-hydroxy-propoxy}-phenyl)-2-methoxy-acetamide,

N-(2-{3-[3-(4-Chloro-phenoxy)-pyrrolidin-1-yl]-2-hydroxy-propoxy}-phenyl)-2,2-dimethyl-propionamide,

25 5-Oxo-hexanoic acid (2-{3-[3-(4-chloro-phenoxy)-pyrrolidin-1-yl]-2-hydroxy-propoxy}-phenyl)-amide,

Hexanoic acid (2-{3-[3-(4-chloro-phenoxy)-pyrrolidin-1-yl]-2-hydroxy-propoxy}-phenyl)-amide,

30 2-Chloro-N-(2-{3-[3-(4-chloro-phenoxy)-pyrrolidin-1-yl]-2-hydroxy-propoxy}-phenyl)-benzamide,

3-Chloro-N-(2-{3-[3-(4-chloro-phenoxy)-pyrrolidin-1-yl]-2-hydroxy-propoxy}-phenyl)-benzamide,

(4R)-N-(2-{3-[3-(4-chlorophenoxy)-1-pyrrolidinyl]-2-hydroxypropoxy}phenyl)-1,3-thiazolidine-4-carboxamide ditrifluoroacetate,

5 Thiophene-2-carboxylic acid (2-{3-[4-(3,4-dichloro-phenoxy)-piperidin-1-yl]-2-hydroxy-propoxy}-phenyl)-amide,

N-(2-{3-[4-(3,4-Dichloro-phenoxy)-piperidin-1-yl]-2-hydroxy-propoxy}-phenyl)-benzamide,

10 N-(2-{3-[4-(3,4-Dichloro-phenoxy)-piperidin-1-yl]-2-hydroxy-propoxy}-phenyl)-nicotinamide,

Pyridine-2-carboxylic acid (2-{3-[4-(3,4-dichloro-phenoxy)-piperidin-1-yl]-2-hydroxy-propoxy}-phenyl)-amide,

N-(2-{3-[4-(3,4-Dichloro-phenoxy)-piperidin-1-yl]-2-hydroxy-propoxy}-phenyl)-isonicotinamide,

15 Cyclohexanecarboxylic acid (2-{3-[4-(3,4-dichloro-phenoxy)-piperidin-1-yl]-2-hydroxy-propoxy}-phenyl)-amide,

N-(2-{3-[4-(3,4-Dichloro-phenoxy)-piperidin-1-yl]-2-hydroxy-propoxy}-phenyl)-3-hydroxy-butyramide,

20 5-Methyl-thiophene-2-carboxylic acid (2-{3-[4-(3,4-dichloro-phenoxy)-piperidin-1-yl]-2-hydroxy-propoxy}-phenyl)-amide,

Cyclobutanecarboxylic acid (2-{3-[4-(3,4-dichloro-phenoxy)-piperidin-1-yl]-2-hydroxy-propoxy}-phenyl)-amide,

N-(2-{3-[4-(3,4-Dichloro-phenoxy)-piperidin-1-yl]-2-hydroxy-propoxy}-phenyl)-propionamide,

25 Pentanoic acid (2-{3-[4-(3,4-dichloro-phenoxy)-piperidin-1-yl]-2-hydroxy-propoxy}-phenyl)-amide,

Pent-4-enoic acid (2-{3-[4-(3,4-dichloro-phenoxy)-piperidin-1-yl]-2-hydroxy-propoxy}-phenyl)-amide,

30 Cyclopentanecarboxylic acid (2-{3-[4-(3,4-dichloro-phenoxy)-piperidin-1-yl]-2-hydroxy-propoxy}-phenyl)-amide,

N-(2-{3-[4-(3,4-Dichloro-phenoxy)-piperidin-1-yl]-2-hydroxy-propoxy}-phenyl)-3-methyl-butyramide,

N-(2-{3-[3-(4-chlorophenoxy)-1-pyrrolidinyl]-2-hydroxypropoxy}phenyl)-2,2,2-trifluoroacetamide hydrochloride,

5 4-(2-{3-[4-(3,4-Dichloro-phenoxy)-piperidin-1-yl]-2-hydroxy-propoxy}-phenylcarbamoyl)-3-methyl-butyric acid,

N-(2-{3-[4-(3,4-Dichloro-phenoxy)-piperidin-1-yl]-2-hydroxy-propoxy}-phenyl)-succinamic acid,

Furan-2-carboxylic acid (2-{3-[3-(4-chloro-phenoxy)-pyrrolidin-1-yl]-2-hydroxy-propoxy}-4-methyl-phenyl)-amide,

1H-Pyrrole-2-carboxylic acid (2-{3-[3-(4-chloro-phenoxy)-pyrrolidin-1-yl]-2-hydroxy-propoxy}-4-methyl-phenyl)-amide,

Thiophene-2-carboxylic acid (2-{3-[3-(4-chloro-phenoxy)-pyrrolidin-1-yl]-2-hydroxy-propoxy}-4-methyl-phenyl)-amide,

15 Cyclopentanecarboxylic acid (2-{3-[3-(4-chloro-phenoxy)-pyrrolidin-1-yl]-2-hydroxy-propoxy}-4-methyl-phenyl)-amide,

5-Methyl-thiophene-2-carboxylic acid (2-{3-[3-(4-chloro-phenoxy)-pyrrolidin-1-yl]-2-hydroxy-propoxy}-4-methyl-phenyl)-amide,

20 3-Chloro-thiophene-2-carboxylic acid (2-{3-[3-(4-chloro-phenoxy)-pyrrolidin-1-yl]-2-hydroxy-propoxy}-4-methyl-phenyl)-amide,

5-Methyl-isoxazole-4-carboxylic acid (2-{3-[3-(4-chloro-phenoxy)-pyrrolidin-1-yl]-2-hydroxy-propoxy}-4-methyl-phenyl)-amide,

[1,2,3]Thiadiazole-4-carboxylic acid (2-{3-[3-(4-chloro-phenoxy)-pyrrolidin-1-yl]-2-hydroxy-propoxy}-4-methyl-phenyl)-amide,

25 3-Methyl-furan-2-carboxylic acid (2-{3-[3-(4-chloro-phenoxy)-pyrrolidin-1-yl]-2-hydroxy-propoxy}-4-methyl-phenyl)-amide,

Cyclopent-1-enecarboxylic acid (2-{3-[3-(4-chloro-phenoxy)-pyrrolidin-1-yl]-2-hydroxy-propoxy}-4-methyl-phenyl)-amide,

30 2-Methyl-furan-3-carboxylic acid (2-{3-[3-(4-chloro-phenoxy)-pyrrolidin-1-yl]-2-hydroxy-propoxy}-4-methyl-phenyl)-amide,

3-Methyl-thiophene-2-carboxylic acid (2-{3-[3-(4-chloro-phenoxy)-pyrrolidin-1-yl]-2-hydroxy-propoxy}-4-methyl-phenyl)-amide,

5-Nitro-1H-pyrazole-3-carboxylic acid (2-{3-[3-(4-chloro-phenoxy)-pyrrolidin-1-yl]-2-hydroxy-propoxy}-4-methyl-phenyl)-amide,

5 Thiophene-3-carboxylic acid (2-{3-[3-(4-chloro-phenoxy)-pyrrolidin-1-yl]-2-hydroxy-propoxy}-4-methyl-phenyl)-amide,

Cyclobutanecarboxylic acid (2-{3-[3-(4-chloro-phenoxy)-pyrrolidin-1-yl]-2-hydroxy-propoxy}-4-methyl-phenyl)-amide,

10 Furan-2-carboxylic acid (2-{3-[3-(4-fluoro-phenoxy)-pyrrolidin-1-yl]-2-hydroxy-propoxy}-4-methyl-phenyl)-amide,

1H-Pyrrole-2-carboxylic acid (2-{3-[3-(4-fluoro-phenoxy)-pyrrolidin-1-yl]-2-hydroxy-propoxy}-4-methyl-phenyl)-amide,

Thiophene-2-carboxylic acid (2-{3-[3-(4-fluoro-phenoxy)-pyrrolidin-1-yl]-2-hydroxy-propoxy}-4-methyl-phenyl)-amide,

15 3-Chloro-thiophene-2-carboxylic acid (2-{3-[3-(4-fluoro-phenoxy)-pyrrolidin-1-yl]-2-hydroxy-propoxy}-4-methyl-phenyl)-amide,

5-Methyl-isoxazole-4-carboxylic acid (2-{3-[3-(4-fluoro-phenoxy)-pyrrolidin-1-yl]-2-hydroxy-propoxy}-4-methyl-phenyl)-amide,

20 3-Methyl-furan-2-carboxylic acid (2-{3-[3-(4-fluoro-phenoxy)-pyrrolidin-1-yl]-2-hydroxy-propoxy}-4-methyl-phenyl)-amide,

Cyclopent-1-enecarboxylic acid (2-{3-[3-(4-fluoro-phenoxy)-pyrrolidin-1-yl]-2-hydroxy-propoxy}-4-methyl-phenyl)-amide,

2-Methyl-furan-3-carboxylic acid (2-{3-[3-(4-fluoro-phenoxy)-pyrrolidin-1-yl]-2-hydroxy-propoxy}-4-methyl-phenyl)-amide,

25 3-Methyl-thiophene-2-carboxylic acid (2-{3-[3-(4-fluoro-phenoxy)-pyrrolidin-1-yl]-2-hydroxy-propoxy}-4-methyl-phenyl)-amide,

5-Chloro-thiophene-2-carboxylic acid (2-{3-[3-(4-fluoro-phenoxy)-pyrrolidin-1-yl]-2-hydroxy-propoxy}-4-methyl-phenyl)-amide,

30 Thiophene-3-carboxylic acid (2-{3-[3-(4-fluoro-phenoxy)-pyrrolidin-1-yl]-2-hydroxy-propoxy}-4-methyl-phenyl)-amide,

2,5-Dimethyl-furan-3-carboxylic acid (2-{3-[3-(4-fluoro-phenoxy)-pyrrolidin-1-yl]-2-hydroxy-propoxy}-4-methyl-phenyl)-amide,

Cyclobutanecarboxylic acid (2-{3-[3-(4-fluoro-phenoxy)-pyrrolidin-1-yl]-2-hydroxy-propoxy}-4-methyl-phenyl)-amide,

5 Furan-3-carboxylic acid (2-{3-[3-(4-fluoro-phenoxy)-pyrrolidin-1-yl]-2-hydroxy-propoxy}-4-methyl-phenyl)-amide,

N-{2-[(3-{3-[(4-fluorophenyl)oxy]-1-pyrrolidinyl}-2-hydroxypropyl)oxy]-4-methylphenyl}-1H-pyrrole-2-carboxamide,

10 N-{2-[(3-{3-[(4-chlorophenyl)oxy]-1-pyrrolidinyl}-2-hydroxypropyl)oxy]-4-methylphenyl}-3-thiophenecarboxamide,

N-{2-[(3-{3-[(4-chlorophenyl)oxy]-1-pyrrolidinyl}-2-hydroxy-2-methylpropyl)oxy]phenyl}-2-thiophenecarboxamide, compound with trifluoroacetic acid,

N-{2-[(3-{3-[(4-fluorophenyl)oxy]-1-pyrrolidinyl}-2-hydroxypropyl)oxy]-4-methylphenyl}-2-thiophenecarboxamide,

15 N-{2-[(3-{3-[(4-chlorophenyl)oxy]-1-pyrrolidinyl}-2-hydroxypropyl)oxy]phenyl}-2-furancarboxamide,

N-{2-[(3-{3-[(4-chlorophenyl)oxy]-1-pyrrolidinyl}-2-hydroxypropyl)oxy]phenyl}-1-pyrrole-2-carboxamide,

20 N-{2-[(3-{3-[(4-chlorophenyl)oxy]-1-pyrrolidinyl}-2-hydroxypropyl)oxy]-4-methylphenyl}-1H-pyrrole-3-carboxamide,

N-{2-[(3-{3-[(4-fluorophenyl)oxy]-1-pyrrolidinyl}-2-hydroxypropyl)oxy]-4-methylphenyl}-2-furancarboxamide,

25 N-{2-[(3-{3-[(4-chlorophenyl)oxy]-1-pyrrolidinyl}-2-hydroxy-2-methylpropyl)oxy]phenyl}cyclopentanecarboxamide, compound with trifluoroacetic acid,

N-(2-{3-[3-(4-Fluoro-phenoxy)-pyrrolidin-1-yl]-2-hydroxy-2-methyl-propoxy}-phenyl)-benzamide,


N-(2-{3-[3-(4-Cyano-phenoxy)-pyrrolidin-1-yl]-2-hydroxy-2-methyl-propoxy}-phenyl)-benzamide,

N-(2-{3-[4-(3,4-Dichloro-phenoxy)-piperidin-1-yl]-2-hydroxy-2-methyl-propoxy}-phenyl)-benzamide.

N-(2-{3-[3-(4-Chloro-phenoxy)-pyrrolidin-1-yl]-2-hydroxy-2-methyl-propoxy}-phenyl)-benzamide, and

N-(2-{3-[4-(3,4-Dichloro-phenylamino)-piperidin-1-yl]-2-hydroxy-2-methyl-propoxy}-phenyl)-benzamide.

The present invention further provides a process for the preparation of a compound of formula (I) as defined above which comprises reacting a compound of general formula



or a salt thereof (e.g. an acid addition salt such as a hydrochloride salt), wherein m, n, t, R¹, R³, R⁴, R⁵, R⁶, R⁷, R⁸, R¹⁶, Q, Z¹ and Z² are as defined in formula (I), with a compound of general formula



or chemically equivalent derivative thereof (e.g. acyl halide or anhydride derivative)
wherein R¹⁵ is as defined in formula (I);

and optionally thereafter forming a pharmaceutically acceptable salt or solvate of the compound of formula (I) obtained.

The process of the invention may conveniently be carried out in a solvent, e.g. an organic solvent such as an alcohol (e.g. methanol or ethanol), a hydrocarbon (e.g. toluene), an amine (e.g. triethylamine or diisopropylethylamine) or acetonitrile at a temperature of, for example, 15°C or above, such as a temperature in the range from 20 to 120°C.

Compounds of formulae (II) and (III) are either commercially available, are well known in the literature or may be prepared easily using known techniques.

5 It will be appreciated by those skilled in the art that in the process of the present invention certain functional groups such as hydroxyl or amino groups in the starting reagents or intermediate compounds may need to be protected by protecting groups. Thus, the preparation of the compounds of formula (I) may involve, at an appropriate stage, the removal of one or more protecting groups.

10 The protection and deprotection of functional groups is described in 'Protective Groups in Organic Chemistry', edited by J.W.F. McOmie, Plenum Press (1973) and 'Protective Groups in Organic Synthesis', 2nd edition, T.W. Greene and P.G.M. Wuts, Wiley-Interscience (1991).

15 The compounds of formula (I) above may be converted to a pharmaceutically acceptable salt or solvate thereof, preferably an acid addition salt such as a hydrochloride, hydrobromide, phosphate, acetate, fumarate, maleate, tartrate, citrate, oxalate, methanesulphonate or *p*-toluenesulphonate.

20 Compounds of formula (I) are capable of existing in stereoisomeric forms. It will be understood that the invention encompasses the use of all geometric and optical isomers of the compounds of formula (I) and mixtures thereof including racemates. The use of tautomers and mixtures thereof also form an aspect of the present invention.

25 The compounds of formula (I) have activity as pharmaceuticals, in particular as modulators of chemokine receptor (especially MIP-1 α chemokine receptor) activity, and may be used in the treatment of autoimmune, inflammatory, proliferative and hyperproliferative diseases and immunologically-mediated diseases including rejection of transplanted organs or tissues and Acquired Immunodeficiency Syndrome (AIDS).

Examples of these conditions are:

- (1) **(the respiratory tract)** airways diseases including chronic obstructive pulmonary disease (COPD) such as irreversible COPD; asthma, such as bronchial, allergic, intrinsic, extrinsic and dust asthma, particularly chronic or inveterate asthma (e.g. late asthma and airways hyper-responsiveness); bronchitis; acute, allergic, atrophic rhinitis and chronic rhinitis including rhinitis caseosa, hypertrophic rhinitis, rhinitis purulenta, rhinitis sicca and rhinitis medicamentosa; membranous rhinitis including croupous, fibrinous and pseudomembranous rhinitis and scrofulous rhinitis; seasonal rhinitis including rhinitis nervosa (hay fever) and vasomotor rhinitis; sarcoidosis, farmer's lung and related diseases, fibroid lung and idiopathic interstitial pneumonia;
- (2) **(bone and joints)** rheumatoid arthritis, seronegative spondyloarthropathies (including ankylosing spondylitis, psoriatic arthritis and Reiter's disease), Behcet's disease, Sjogren's syndrome and systemic sclerosis;
- (3) **(skin)** psoriasis, atopic dermatitis, contact dermatitis and other eczematous dermatides, seborrhoetic dermatitis, Lichen planus, Pemphigus, bullous Pemphigus, Epidermolysis bullosa, urticaria, angiodermas, vasculitides, erythemas, cutaneous eosinophilias, uveitis, Alopecia areata and vernal conjunctivitis;
- (4) **(gastrointestinal tract)** Coeliac disease, proctitis, eosinophilic gastro-enteritis, mastocytosis, Crohn's disease, ulcerative colitis, food-related allergies which have effects remote from the gut, e.g., migraine, rhinitis and eczema;
- (5) **(other tissues and systemic disease)** multiple sclerosis, atherosclerosis, Acquired Immunodeficiency Syndrome (AIDS), lupus erythematosus, systemic lupus, erythematosus, Hashimoto's thyroiditis, myasthenia gravis, type I diabetes, nephrotic syndrome, eosinophilia fascitis, hyper IgE syndrome, lepromatous leprosy, Sezary syndrome and idiopathic thrombocytopenia purpura;

- (6) (allograft rejection) acute and chronic following, for example, transplantation of kidney, heart, liver, lung, bone marrow, skin and cornea; and chronic graft versus host disease;
- 5 (7) cancers, especially non-small cell lung cancer (NSCLC) and squamous sarcoma;
- (8) diseases in which angiogenesis is associated with raised chemokine levels (e.g. NSCLC); and
- 10 (9) cystic fibrosis, stroke, re-perfusion injury in the heart, brain, peripheral limbs and sepsis.

Thus, the present invention provides a compound of formula (I), or a pharmaceutically-acceptable salt or solvate thereof, as hereinbefore defined for use in therapy.

15

In a further aspect, the present invention provides the use of a compound of formula (I), or a pharmaceutically acceptable salt or solvate thereof, as hereinbefore defined in the manufacture of a medicament for use in therapy.

- 20 In the context of the present specification, the term "therapy" also includes "prophylaxis" unless there are specific indications to the contrary. The terms "therapeutic" and "therapeutically" should be construed accordingly.

The invention also provides a method of treating an inflammatory disease in a patient
25 suffering from, or at risk of, said disease, which comprises administering to the patient a therapeutically effective amount of a compound of formula (I), or a pharmaceutically acceptable salt or solvate thereof, as hereinbefore defined.

The invention still further provides a method of treating an airways disease in a patient
30 suffering from, or at risk of, said disease, which comprises administering to the patient a

therapeutically effective amount of a compound of formula (I), or a pharmaceutically acceptable salt or solvate thereof, as hereinbefore defined.

For the above-mentioned therapeutic uses the dosage administered will, of course, vary
5 with the compound employed, the mode of administration, the treatment desired and the disorder indicated. The daily dosage of the compound of formula (I) may be in the range from 0.001 mg/kg to 30 mg/kg.

The compounds of formula (I) and pharmaceutically acceptable salts and solvates thereof
10 may be used on their own but will generally be administered in the form of a pharmaceutical composition in which the formula (I) compound/salt/solvate (active ingredient) is in association with a pharmaceutically acceptable adjuvant, diluent or carrier. Depending on the mode of administration, the pharmaceutical composition will preferably comprise from 0.05 to 99 %w (per cent by weight), more preferably from 0.05 to 80 %w,
15 still more preferably from 0.10 to 70 %w, and even more preferably from 0.10 to 50 %w, of active ingredient, all percentages by weight being based on total composition.

The present invention also provides a pharmaceutical composition comprising a compound of formula (I), or a pharmaceutically acceptable salt or solvate thereof, as hereinbefore
20 defined, in association with a pharmaceutically acceptable adjuvant, diluent or carrier.

The invention further provides a process for the preparation of a pharmaceutical composition of the invention which comprises mixing a compound of formula (I), or a pharmaceutically acceptable salt or solvate thereof, as hereinbefore defined, with a
25 pharmaceutically acceptable adjuvant, diluent or carrier.

The pharmaceutical compositions may be administered topically (e.g. to the lung and/or airways or to the skin) in the form of solutions, suspensions, heptafluoroalkane aerosols and dry powder formulations; or systemically, e.g. by oral administration in the form of
30 tablets, capsules, syrups, powders or granules, or by parenteral administration in the form

of solutions or suspensions, or by subcutaneous administration or by rectal administration in the form of suppositories or transdermally.

The invention will now be further explained by reference to the following illustrative
5 examples, in which ^1H NMR spectra were recorded on Varian Unity Inova 400. The central solvent peak of chloroform-*d* (δ_{H} 7.27 ppm) were used as internal standard. Low resolution mass spectra and accurate mass determination were recorded on a Hewlett-Packard 1100 LC-MS system equipped with APCI /ESI ionisation chambers.

All solvents and commercial reagents were laboratory grade and used as received.

10 The nomenclature used for the compounds was generated with ACD/IUPAC Name Pro.

The following abbreviations are used in the examples:

NMP : 1-Methyl-2-pyrrolidinone

DIEA: N,N-Diisopropylethylamine

HBTU: 2-(1H-Benzotriazol-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate

15 HoBT: 1-Hydroxybenzotriazole

THF : Tetrahydrofuran

Example 1

N-(5-Chloro-2-{3-[3-(4-chloro-phenoxy)-pyrrolidin-1-yl]-2-hydroxy-propoxy}-
20 phenyl)-isobutyramide

a) *N*-(5-Chloro-2-hydroxy-phenyl)-isobutyramide

In a flask was added 4-chloro-2-aminophenol (1.2 g, 8.39 mmole) and water (25 ml).

The suspension was vigorously stirred and isobutyric anhydride (1.6 ml, 10.5 mmole) was
25 added. The mixture was heated to 60°C for 30 minutes under vigorous stirring. The emulsion was cooled, and a precipitate was formed, which was collected through filtration.

The solid was washed twice with water on the filter and was finally dried to give 1.4 g (78%) of the sub-title compound as a white solid.

¹H-NMR (400 MHz, DMSO-*d*₆) δ: 10.11 (1H, s); 9.12 (1H, s); 7.94 (1H, d, *J* 2.5 Hz); 6.95 (1H, dd, *J* 8.7 2.6 Hz); 6.84 (1H, d, *J* 8.5 Hz); 2.79 (1H, p, *J* 6.7 Hz); 1.08 (6H, d, *J* 6.8 Hz)

b) *N*-(5-Chloro-2-oxiranylmethoxy-phenyl)-isobutyramide

5 In a vial was added the compound obtained in a) (0.4 g, 1.87 mmole), epibromohydrin (0.28 g, 2.06 mmole), K₂CO₃ (0.5 g, 3.7 mmole) and DMF (2 ml). The vial was sealed and heated with stirring (2 hours, 60°C). The mixture was then partitioned between EtOAc and water, and the organic phase was washed twice with water and once with brine, and was finally evaporated to give a brown solid. The crude epoxide was purified on silica, to give
10 0.22 g (44%) of the sub-title compound as a white solid.

c) In a vial was added the compound obtained in b) (0.026 g, 0.13 mmole), 3-(4-chlorophenoxy)-pyrrolidine (0.035 g, 0.13 mmole) in ethanol (2 ml). The vial was sealed and heated with stirring at 75°C for 3 hours. The solution was allowed to cool, and the
15 solvent was evaporated. The crude product was purified on silica, and the pure fractions were collected. The title compound was lyophilized as the hydrochloride, giving 0.055 g (84%) as a white solid. The compound was a mixture of four stereoisomers, which had an effect on the NMR-spectra.

20 ¹H-NMR (400 MHz, DMSO-*d*₆) δ: 10.84-10.34 (1H, m); 9.12 (1H, s); 8.09 (1H, s); 7.36 (2H, dd, *J* 9.2 1.3 Hz); 7.11-7.00 (3H, m); 7.00 (2H, d, *J* 8.8 Hz); 6.22-6.06 (1H, m); 5.22-5.10 (1H, m); 4.34 (1H, bs); 4.08-3.96 (1.5H, m); 3.95-3.87 (1H, m); 3.83-3.66 (1.5H, m); 3.61-3.23 (3H, m); 2.86 (1H, sept, *J* 6.6 Hz); 2.64-2.51 (1/2H, m); 2.36-2.14 (1H, m); 2.14-2.00 (1/2H, m); 1.08 (6H, d, *J* 6.7 Hz)

25 APCI-MS: *m/z* 467.2 [MH⁺]

Aniline Intermediate 1

1-(2-aminophenoxy)-3-[4-(3,4-dichlorophenoxy)-1-piperidinyl]-2-propanol dihydrochloride

N-(2-{3-[4-(3,4-dichlorophenoxy)-1-piperidinyl]-2-hydroxypropoxy}phenyl)acetamide (1.418g, 3.13 mmol, prepared by analogy to Example 1) was dissolved in 50ml HCl (35%/aq, puriss) and refluxed overnight. The product precipitated and was filtered and dried to give 0.835 g (65%) of the title compound.

5

APCI-MS m/z: 411, 413 [MH⁺]

¹H NMR (400 MHz, CDCl₃) : δ 8.39-3.31 (m, 2H), 7.31(d, 1H), 7.01-6.98(m, 3H), 6.94-6.91(m, 1H), 6.75(dd, 1H), 4.31(m, 1H), 4.12-4.02 (m, 2H), 3.92(dd, 1H), 2.90(m, 1H), 2.69(m, 1H), 2.62-2.51(m, 2H), 2.46(dd, 1H), 2.34(m, 1H), 2.18(s, 3H), 2.04-1.93(m, 2H), 1.89-1.77(m, 2H).

10

Aniline Intermediate 2

1-[(2-aminophenyl)oxy]-3-{3-[(4-chlorophenyl)oxy]-1-pyrrolidinyl}-2-propanol dihydrochloride

15

Prepared according to the method described in Aniline Intermediate 1.

APCI-MS m/z: 363, 365 [MH⁺]

The intermediate anilines 1 and 2 described above were used in the following examples.

20

Example 2

Thiophene-2-carboxylic acid (2-{3-[3-(4-chloro-phenoxy)-pyrrolidin-1-yl]-2-hydroxy-propoxy}-phenyl)-amide

25

To a solution of 80 uL 0.2M 2-thiophenecarboxylic acid in NMP were HBTU (80uL, 0.2M/NMP), HoBT (80uL, 0.2M/NMP), DIEA (30uL, 0.5M/NMP) and pyridine (30uL, 0.5M/NMP) added and stirred for 30 minutes before 1-[(2-aminophenyl)oxy]-3-{3-[(4-chlorophenyl)oxy]-1-pyrrolidinyl}-2-propanol (75uL, 0.2M/NMP) was added. The mixture was stirred overnight at roomtemperature before it was concentrated under reduced

pressure to dryness. The product was diluted with 1000uL dichloromethane and washed with with sat. NaHCO₃/aq (800uL), 1.8% HCl/aq (800uL) and sat. NaCl/aq.

The organic layer was concentrated under reduced pressure to dryness and used without further purification. Yield 3.6mg, 51%

5

APCI-MS m/z: 473.2 [MH⁺]

¹H NMR (400 MHz, CD₃OD) : δ 7.88-7.85 (d, 1H), 7.74-7.65 (m, 2H), 7.34-7.28 (m, 2H), 7.27-7.21 (m, 1H), 7.20-7.15 (m, 1H), 7.14-7.09 (dd, 1H), 7.06-7.00 (m, 1H), 6.96-6.91 (m, 2H), 5.18-5.12 (m, 1H), 4.39-4.30 (m, 1H), 4.19-3.24 (m, 9H), 2.66-2.11 (m, 3H)

10

The following Examples 3 to 53 were prepared by methods analogous to the method described in Example 2.

Example 3

15 **N-[(2-{3-[3-(4-Chloro-phenoxy)-pyrrolidin-1-yl]-2-hydroxy-propoxy}-phenylcarbamoyl)-methyl]-benzamide**

APCI-MS m/z: 524.3 [MH⁺]

Example 4

20 **Pyrazine-2-carboxylic acid (2-{3-[3-(4-chloro-phenoxy)-pyrrolidin-1-yl]-2-hydroxy-propoxy}-phenyl)-amide**

APCI-MS m/z: 469.2 [MH⁺]

25

Example 5

Cyclohexanecarboxylic acid (2-{3-[3-(4-chloro-phenoxy)-pyrrolidin-1-yl]-2-hydroxy-propoxy}-phenyl)-amide

30 APCI-MS m/z: 473.3 [MH⁺]

Example 6

N-(2-{3-[3-(4-Chloro-phenoxy)-pyrrolidin-1-yl]-2-hydroxy-propoxy}-phenyl)-
phthalamic acid methyl ester

5

APCI-MS m/z: 525.2 [MH⁺]

Example 7

N-(2-{3-[3-(4-Chloro-phenoxy)-pyrrolidin-1-yl]-2-hydroxy-propoxy}-phenyl)-3-
10 hydroxy-butyramide

APCI-MS m/z: 449.2 [MH⁺]

Example 8

N-(2-{3-[3-(4-Chloro-phenoxy)-pyrrolidin-1-yl]-2-hydroxy-propoxy}-phenyl)-2-
15 ureido-acetamide

APCI-MS m/z: 463.2 [MH⁺]

Example 9

4-Acetylamino-N-(2-{3-[3-(4-chloro-phenoxy)-pyrrolidin-1-yl]-2-hydroxy-propoxy}-
20 phenyl)-butyramide

APCI-MS m/z: 490.3 [MH⁺]

25

Example 10

1-Acetyl-piperidine-4-carboxylic acid (2-{3-[3-(4-chloro-phenoxy)-pyrrolidin-1-yl]-2-
hydroxy-propoxy}-phenyl)-amide

30 APCI-MS m/z: 516.3 [MH⁺]

Example 11

N-(2-{3-[3-(4-Chloro-phenoxy)-pyrrolidin-1-yl]-2-hydroxy-propoxy}-phenyl)-3-methoxy-benzamide

5

APCI-MS m/z: 497.2 [MH⁺]

Example 12

2-Acetylamino-N-(2-{3-[3-(4-chloro-phenoxy)-pyrrolidin-1-yl]-2-hydroxy-propoxy}-phenyl)-3-methyl-butyramide

10

APCI-MS m/z: 504.3 [MH⁺]

Example 13

2-Acetylamino-N-(2-{3-[3-(4-chloro-phenoxy)-pyrrolidin-1-yl]-2-hydroxy-propoxy}-phenyl)-3-hydroxy-butyramide

15

APCI-MS m/z: 506.2 [MH⁺]

Example 14

Adamantane-1-carboxylic acid (2-{3-[3-(4-chloro-phenoxy)-pyrrolidin-1-yl]-2-hydroxy-propoxy}-phenyl)-amide

20

APCI-MS m/z: 525.3 [MH⁺]

25

Example 15

2-Acetylamino-N-(2-{3-[3-(4-chloro-phenoxy)-pyrrolidin-1-yl]-2-hydroxy-propoxy}-phenyl)-3-phenyl-propionamide

30

APCI-MS m/z: 552.3 [MH⁺]

Example 16

N-(2-{3-[3-(4-Chloro-phenoxy)-pyrrolidin-1-yl]-2-hydroxy-propoxy}-phenyl)-2-methoxy-benzamide

5

APCI-MS m/z: 497.2 [MH⁺]

Example 17

5-Methyl-thiophene-2-carboxylic acid (2-{3-[3-(4-chloro-phenoxy)-pyrrolidin-1-yl]-2-hydroxy-propoxy}-phenyl)-amide

10

APCI-MS m/z: 487.2 [MH⁺]

Example 18

1-Acetyl-pyrrolidine-2-carboxylic acid (2-{3-[3-(4-chloro-phenoxy)-pyrrolidin-1-yl]-2-hydroxy-propoxy}-phenyl)-amide

15

APCI-MS m/z: 502.3 [MH⁺]

Example 19

1,5-Dimethyl-1H-pyrazole-3-carboxylic acid (2-{3-[3-(4-chloro-phenoxy)-pyrrolidin-1-yl]-2-hydroxy-propoxy}-phenyl)-amide

20

APCI-MS m/z: 485.3 [MH⁺]

25

Example 20

5-Oxo-pyrrolidine-2-carboxylic acid (2-{3-[3-(4-chloro-phenoxy)-pyrrolidin-1-yl]-2-hydroxy-propoxy}-phenyl)-amide

APCI-MS m/z: 474.2 [MH⁺]

30

Example 21

1H-Indole-6-carboxylic acid (2-{3-[3-(4-chloro-phenoxy)-pyrrolidin-1-yl]-2-hydroxy-propoxy}-phenyl)-amide

5

APCI-MS m/z: 506.2 [MH⁺]

Example 22

Cyclobutanecarboxylic acid (2-{3-[3-(4-chloro-phenoxy)-pyrrolidin-1-yl]-2-hydroxy-propoxy}-phenyl)-amide

10

APCI-MS m/z: 445.3 [MH⁺]

Example 23

N-(2-{3-[3-(4-Chloro-phenoxy)-pyrrolidin-1-yl]-2-hydroxy-propoxy}-phenyl)-propionamide

15

APCI-MS m/z: 419.2 [MH⁺]

Example 24

Pentanoic acid (2-{3-[3-(4-chloro-phenoxy)-pyrrolidin-1-yl]-2-hydroxy-propoxy}-phenyl)-amide

20

APCI-MS m/z: 447.3 [MH⁺]

25

Example 25

Pent-4-enoic acid (2-{3-[3-(4-chloro-phenoxy)-pyrrolidin-1-yl]-2-hydroxy-propoxy}-phenyl)-amide

30 APCI-MS m/z: 445.3 [MH⁺]

Example 26

Cyclopentanecarboxylic acid (2-{3-[3-(4-chloro-phenoxy)-pyrrolidin-1-yl]-2-hydroxy-propoxy}-phenyl)-amide

5

APCI-MS m/z: 459.3 [MH⁺]

Example 27

Cyclopropanecarboxylic acid (2-{3-[3-(4-chloro-phenoxy)-pyrrolidin-1-yl]-2-hydroxy-propoxy}-phenyl)-amide

10

APCI-MS m/z: 431.2 [MH⁺]

Example 28

N-(2-{3-[3-(4-Chloro-phenoxy)-pyrrolidin-1-yl]-2-hydroxy-propoxy}-phenyl)-isobutyramide

15

APCI-MS m/z: 433.3 [MH⁺]

Example 29

N-(2-{3-[3-(4-Chloro-phenoxy)-pyrrolidin-1-yl]-2-hydroxy-propoxy}-phenyl)-2-methylsulfanyl-acetamide

20

APCI-MS m/z: 451.2 [MH⁺]

25

Example 30

2-Acetylamino-N-(2-{3-[3-(4-chloro-phenoxy)-pyrrolidin-1-yl]-2-hydroxy-propoxy}-phenyl)-propionamide

30

APCI-MS m/z: 476.2 [MH⁺]

Example 31

N-(2-{3-[3-(4-Chloro-phenoxy)-pyrrolidin-1-yl]-2-hydroxy-propoxy}-phenyl)-
butyramide

5

APCI-MS m/z: 433.3 [MH⁺]

Example 32

N-(2-{3-[3-(4-Chloro-phenoxy)-pyrrolidin-1-yl]-2-hydroxy-propoxy}-phenyl)-3-
methyl-butyramide

10

APCI-MS m/z: 447.3 [MH⁺]

Example 33

N-(2-{3-[3-(4-Chloro-phenoxy)-pyrrolidin-1-yl]-2-hydroxy-propoxy}-phenyl)-2-
methoxy-acetamide

15

APCI-MS m/z: 435.2 [MH⁺]

Example 34

N-(2-{3-[3-(4-Chloro-phenoxy)-pyrrolidin-1-yl]-2-hydroxy-propoxy}-phenyl)-2,2-
dimethyl-propionamide

20

APCI-MS m/z: 447.2 [MH⁺]

25

Example 35

5-Oxo-hexanoic acid (2-{3-[3-(4-chloro-phenoxy)-pyrrolidin-1-yl]-2-hydroxy-
prop xy}-phenyl)-amide

30

APCI-MS m/z: 475.3 [MH⁺]

Example 36

Hexanoic acid (2-{3-[3-(4-chloro-phenoxy)-pyrrolidin-1-yl]-2-hydroxy-propoxy}-phenyl)-amide

5

APCI-MS m/z: 461.3 [MH⁺]

Example 37

2-Chloro-N-(2-{3-[3-(4-chloro-phenoxy)-pyrrolidin-1-yl]-2-hydroxy-propoxy}-phenyl)-benzamide

10

APCI-MS m/z: 501.2 , 503.2 [MH⁺]

Example 38

3-Chloro-N-(2-{3-[3-(4-chloro-phenoxy)-pyrrolidin-1-yl]-2-hydroxy-propoxy}-phenyl)-benzamide

15

APCI-MS m/z: 501.2 , 503.2 [MH⁺]

Example 39

(4R)-N-(2-{3-[3-(4-chlorophenoxy)-1-pyrrolidinyl]-2-hydroxypropoxy}phenyl)-1,3-thiazolidine-4-carboxamide ditrifluoroacetate

20

APCI-MS m/z: 478.2 [MH⁺]

25

Example 40

Thiophene-2-carboxylic acid (2-{3-[4-(3,4-dichloro-phenoxy)-piperidin-1-yl]-2-hydroxy-propoxy}-phenyl)-amide

30 APCI-MS m/z: 521.0 , 523.0 [MH⁺]

Example 41

N-(2-{3-[4-(3,4-Dichloro-phenoxy)-piperidin-1-yl]-2-hydroxy-propoxy}-phenyl)-benzamide

5

APCI-MS m/z: 515.2 , 517.2 [MH⁺]

Example 42

N-(2-{3-[4-(3,4-Dichloro-phenoxy)-piperidin-1-yl]-2-hydroxy-propoxy}-phenyl)-nicotinamide

10

APCI-MS m/z: 516.2 , 518.2 [MH⁺]

Example 43

Pyridine-2-carboxylic acid (2-{3-[4-(3,4-dichloro-phenoxy)-piperidin-1-yl]-2-hydroxy-propoxy}-phenyl)-amide

15

APCI-MS m/z: 516.2 , 518.2 [MH⁺]

Example 44

N-(2-{3-[4-(3,4-Dichloro-phenoxy)-piperidin-1-yl]-2-hydroxy-propoxy}-phenyl)-isonicotinamide

20

APCI-MS m/z: 516.2 , 518.2 [MH⁺]

25

Example 45

Cyclohexanecarboxylic acid (2-{3-[4-(3,4-dichloro-phenoxy)-piperidin-1-yl]-2-hydroxy-propoxy}-phenyl)-amide

30

APCI-MS m/z: 521.3 , 523.3 [MH⁺]

Example 46

N-(2-{3-[4-(3,4-Dichloro-phenoxy)-piperidin-1-yl]-2-hydroxy-propoxy}-phenyl)-3-hydroxy-butyramide

5

APCI-MS m/z: 497.2 , 499.3 [MH⁺]

Example 47

5-Methyl-thiophene-2-carboxylic acid (2-{3-[4-(3,4-dichloro-phenoxy)-piperidin-1-yl]-2-hydroxy-propoxy}-phenyl)-amide

10

APCI-MS m/z: 535.2 , 537.2 [MH⁺]

Example 48

Cyclobutanecarboxylic acid (2-{3-[4-(3,4-dichloro-phenoxy)-piperidin-1-yl]-2-hydroxy-propoxy}-phenyl)-amide

15

APCI-MS m/z: 493.3 , 495.2 [MH⁺]

Example 49

N-(2-{3-[4-(3,4-Dichloro-phenoxy)-piperidin-1-yl]-2-hydroxy-propoxy}-phenyl)-propionamide

20

APCI-MS m/z: 467.2 , 469.2 [MH⁺]

25

Example 50

Pentanoic acid (2-{3-[4-(3,4-dichloro-phenoxy)-piperidin-1-yl]-2-hydroxy-propoxy}-phenyl)-amide

APCI-MS m/z: 495.3 , 497.3 [MH⁺]

30

Example 51

Pent-4-enoic acid (2-{3-[4-(3,4-dichloro-phenoxy)-piperidin-1-yl]-2-hydroxy-propoxy}-phenyl)-amide

APCI-MS m/z: 493.3 , 495.2 [MH⁺]

Example 52

Cyclopentanecarboxylic acid (2-{3-[4-(3,4-dichloro-phenoxy)-piperidin-1-yl]-2-hydroxy-propoxy}-phenyl)-amide

APCI-MS m/z: 507.3 , 509.3 [MH⁺]

Example 53

N-(2-{3-[4-(3,4-Dichloro-phenoxy)-piperidin-1-yl]-2-hydroxy-propoxy}-phenyl)-3-methyl-butyramide

APCI-MS m/z: 495.3, 497.3 [MH⁺]

Example 54

N-(2-{3-[3-(4-chlorophenoxy)-1-pyrrolidinyl]-2-hydroxypropoxy}phenyl)-2,2,2-trifluoroacetamide hydrochloride

A mixture of 1-(2-aminophenoxy)-3-[3-(4-chlorophenoxy)-1-pyrrolidinyl]-2-propanol (10mg, 0.022mmol), dichloromethane (3ml) and Triethyl amine was cooled in an ice bath. A solution of Trifluoro acetic anhydride (3.5µl, 0.025mmol) in dichloromethane (2ml) was then added and the mixture stirred at 0°C until reaction completion. The mixture was diluted with dichloromethane, washed with 1M H₂SO₄, water, dried over sodium sulphate and concentrated to give an oil. The oil was treated with 1.0M ethereal HCl solution to give the product as solid (9mg).

APCI-MS: m/z 459, 460 [MH⁺]

Example 55

5 **4-(2-{3-[4-(3,4-Dichloro-phenoxy)-piperidin-1-yl]-2-hydroxy-propoxy}-phenylcarbamoyl)-3-methyl-butyric acid**

1-(2-aminophenoxy)-3-[4-(3,4-dichlorophenoxy)-1-piperidiny]-2-propanol (75uL, 0.2M/NMP) was mixed with 3-methyl glutaric anhydride (3eq, 225uL 0.2M /NMP) to get
10 a product containing both ester and amide. After evaporation of the mixture it was treated with 3 eq 0.5M LiOH in (THF/water 1:4) for two hours at 80°C to hydrolyse the ester. The reaction mixture was diluted with more water (2mL) and the desired product was extracted with 5x500uL EtOAc which was evaporated to dryness.

15 APCI-MS m/z: 539.2 , 541.2 [MH⁺]

Example 56

N-(2-{3-[4-(3,4-Dichloro-phenoxy)-piperidin-1-yl]-2-hydroxy-propoxy}-phenyl)-succinamic acid

20

Prepared according to the method described in Example 55.

APCI-MS m/z: 511.2 , 513.2 [MH⁺]

25 **Aniline Intermediate 3**

1-(2-amino-5-methylphenoxy)-3-[3-(4-chlorophenoxy)-1-pyrrolidiny]-2-propanol

APCI-MS m/z: 377.2 , 379.1 [MH⁺]

¹H NMR (400 MHz, CDCl₃) : δ 7.26-7.21 (m, 2H), 6.79-6.74 (m, 2H), 6.67-6.62 (m, 3H), 4.83-4.76 (m, 1H), 4.15-4.06 (m, 1H), 4.04-4.00 (d, 2H), 3.73-3.64 (s, 2H), 3.47-3.35 (s, 1H), 3.14 – 2.56 (m, 6H), 2.36-2.22(m, 4H), 2.05-1.95(m, 1H)

5 **Aniline Intermediate 4**

1-(2-amino-5-methylphenoxy)-3-[3-(4-fluorophenoxy)-1-pyrrolidinyl]-2-propanol

APCI-MS m/z: 361.1 [MH⁺]

10 ¹H NMR (400 MHz, CDCl₃) : δ 7.00-6.94 (m, 2H), 6.81-6.76 (m, 2H), 6.67-6.62 (m, 3H), 4.81-4.74 (m, 1H), 4.15-4.06 (m, 1H), 4.03-3.99 (m, 2H), 3.88-3.36 (m, 3H), 3.12 – 2.56 (m, 6H), 2.33-2.23(m, 4H), 2.05-1.96(m, 1H)

The compounds of Examples 57 to 85 were prepared using one of the Aniline

15 Intermediates 3 and 4.

Example 57

Furan-2-carboxylic acid (2-{3-[3-(4-chloro-phenoxy)-pyrrolidin-1-yl]-2-hydroxy-propoxy}-4-methyl-phenyl)-amide

20

APCI-MS m/z: 471.5 , 473.5 [MH⁺]

Example 58

1H-Pyrrole-2-carboxylic acid (2-{3-[3-(4-chloro-phenoxy)-pyrrolidin-1-yl]-2-hydroxy-propoxy}-4-methyl-phenyl)-amide

25

APCI-MS m/z: 470.5 , 472.5 [MH⁺]

Example 59

Thiophene-2-carboxylic acid (2-{3-[3-(4-chloro-phenoxy)-pyrrolidin-1-yl]-2-hydroxy-propoxy}-4-methyl-phenyl)-amide

APCI-MS m/z: 487.5 , 489.5 [MH+]

5

Example 60

Cyclopentanecarboxylic acid (2-{3-[3-(4-chloro-phenoxy)-pyrrolidin-1-yl]-2-hydroxy-propoxy}-4-methyl-phenyl)-amide

10 APCI-MS m/z: 473.6 , 475.5 [MH+]

Example 61

5-Methyl-thiophene-2-carboxylic acid (2-{3-[3-(4-chloro-phenoxy)-pyrrolidin-1-yl]-2-hydroxy-propoxy}-4-methyl-phenyl)-amide

15

APCI-MS m/z: 501.5 , 503.5 [MH+]

Example 62

3-Chloro-thiophene-2-carboxylic acid (2-{3-[3-(4-chloro-phenoxy)-pyrrolidin-1-yl]-2-hydroxy-propoxy}-4-methyl-phenyl)-amide

20

APCI-MS m/z: 521.5 , 532.5 [MH+]

Example 63

25 5-Methyl-isoxazole-4-carboxylic acid (2-{3-[3-(4-chloro-phenoxy)-pyrrolidin-1-yl]-2-hydroxy-propoxy}-4-methyl-phenyl)-amide

APCI-MS m/z: 486.5 , 488.6 [MH+]

30 **Example 64**

[1,2,3]Thiadiazole-4-carboxylic acid (2-{3-[3-(4-chloro-phenoxy)-pyrrolidin-1-yl]-2-hydroxy-propoxy}-4-methyl-phenyl)-amide

APCI-MS m/z: 489.5 , 491.5 [MH+]

5

Example 65

3-Methyl-furan-2-carboxylic acid (2-{3-[3-(4-chloro-phenoxy)-pyrrolidin-1-yl]-2-hydroxy-propoxy}-4-methyl-phenyl)-amide

10 APCI-MS m/z: 485.5 , 487.6 [MH+]

Example 66

Cyclopent-1-enecarboxylic acid (2-{3-[3-(4-chloro-phenoxy)-pyrrolidin-1-yl]-2-hydroxy-propoxy}-4-methyl-phenyl)-amide

15

APCI-MS m/z: 471.6 , 473.6 [MH+]

Example 67

2-Methyl-furan-3-carboxylic acid (2-{3-[3-(4-chloro-phenoxy)-pyrrolidin-1-yl]-2-hydroxy-propoxy}-4-methyl-phenyl)-amide

20

APCI-MS m/z: 485.6 , 487.6 [MH+]

Example 68

3-Methyl-thiophene-2-carboxylic acid (2-{3-[3-(4-chloro-phenoxy)-pyrrolidin-1-yl]-2-hydroxy-propoxy}-4-methyl-phenyl)-amide

25

APCI-MS m/z: 501.6 , 503.5 [MH+]

30 **Example 69**

5-Nitro-1H-pyrazole-3-carboxylic acid (2-{3-[3-(4-chloro-phenoxy)-pyrrolidin-1-yl]-2-hydroxy-propoxy}-4-methyl-phenyl)-amide

APCI-MS m/z: 516.5 , 518.5 [MH+]

5

Example 70

Thiophene-3-carboxylic acid (2-{3-[3-(4-chloro-phenoxy)-pyrrolidin-1-yl]-2-hydroxy-propoxy}-4-methyl-phenyl)-amide

10 APCI-MS m/z: 487.5 , 489.5 [MH+]

Example 71

Cyclobutanecarboxylic acid (2-{3-[3-(4-chloro-phenoxy)-pyrrolidin-1-yl]-2-hydroxy-propoxy}-4-methyl-phenyl)-amide

15

APCI-MS m/z: 459.5 , 461.5 [MH+]

Example 72

Furan-2-carboxylic acid (2-{3-[3-(4-fluoro-phenoxy)-pyrrolidin-1-yl]-2-hydroxy-propoxy}-4-methyl-phenyl)-amide

20

APCI-MS m/z: 455.5 [MH+]

Example 73

1H-Pyrrole-2-carboxylic acid (2-{3-[3-(4-fluoro-phenoxy)-pyrrolidin-1-yl]-2-hydroxy-propoxy}-4-methyl-phenyl)-amide

25

APCI-MS m/z: 454.6 [MH+]

30 **Example 74**

Thiophene-2-carboxylic acid (2-{3-[3-(4-fluoro-phenoxy)-pyrrolidin-1-yl]-2-hydroxy-propoxy}-4-methyl-phenyl)-amide

APCI-MS m/z: 471.5 [MH⁺]

5

Example 75

3-Chloro-thiophene-2-carboxylic acid (2-{3-[3-(4-fluoro-phenoxy)-pyrrolidin-1-yl]-2-hydroxy-propoxy}-4-methyl-phenyl)-amide

10 APCI-MS m/z: 505.5 , 507.5 [MH⁺]

Example 76

5-Methyl-isoxazole-4-carboxylic acid (2-{3-[3-(4-fluoro-phenoxy)-pyrrolidin-1-yl]-2-hydroxy-propoxy}-4-methyl-phenyl)-amide

15

APCI-MS m/z: 470.5 [MH⁺]

Example 77

3-Methyl-furan-2-carboxylic acid (2-{3-[3-(4-fluoro-phenoxy)-pyrrolidin-1-yl]-2-hydroxy-propoxy}-4-methyl-phenyl)-amide

20

APCI-MS m/z: 469.6 [MH⁺]

Example 78

25 Cyclopent-1-enecarboxylic acid (2-{3-[3-(4-fluoro-phenoxy)-pyrrolidin-1-yl]-2-hydroxy-propoxy}-4-methyl-phenyl)-amide

APCI-MS m/z: 455.6 [MH⁺]

30 Example 79

2-Methyl-furan-3-carboxylic acid (2-{3-[3-(4-fluoro-phenoxy)-pyrrolidin-1-yl]-2-hydroxy-propoxy}-4-methyl-phenyl)-amide

APCI-MS m/z: 469.6 [MH⁺]

5

Example 80

3-Methyl-thiophene-2-carboxylic acid (2-{3-[3-(4-fluoro-phenoxy)-pyrrolidin-1-yl]-2-hydroxy-propoxy}-4-methyl-phenyl)-amide

10 APCI-MS m/z: 485.5 [MH⁺]

Example 81

5-Chloro-thiophene-2-carboxylic acid (2-{3-[3-(4-fluoro-phenoxy)-pyrrolidin-1-yl]-2-hydroxy-propoxy}-4-methyl-phenyl)-amide

15

APCI-MS m/z: 505.5 , 507.5 [MH⁺]

Example 82

Thiophene-3-carboxylic acid (2-{3-[3-(4-fluoro-phenoxy)-pyrrolidin-1-yl]-2-hydroxy-propoxy}-4-methyl-phenyl)-amide

20

APCI-MS m/z: 471.5 [MH⁺]

Example 83

2,5-Dimethyl-furan-3-carboxylic acid (2-{3-[3-(4-fluoro-phenoxy)-pyrrolidin-1-yl]-2-hydroxy-propoxy}-4-methyl-phenyl)-amide

25

APCI-MS m/z: 483.6 [MH⁺]

30 **Example 84**

Cyclobutanecarboxylic acid (2-{3-[3-(4-fluoro-phenoxy)-pyrrolidin-1-yl]-2-hydroxy-propoxy}-4-methyl-phenyl)-amide

APCI-MS m/z: 443.6 [MH⁺]

5

Example 85

Furan-3-carboxylic acid (2-{3-[3-(4-fluoro-phenoxy)-pyrrolidin-1-yl]-2-hydroxy-propoxy}-4-methyl-phenyl)-amide

10 APCI-MS m/z: 455.5 [MH⁺]

Example 86

N-{2-[(3-{3-[(4-fluorophenyl)oxy]-1-pyrrolidinyl}-2-hydroxypropyl)oxy]-4-methylphenyl}-1H-pyrrole-2-carboxamide

15

APCI-MS: m/z 454.1 [M+H⁺]

Example 87

N-{2-[(3-{3-[(4-chlorophenyl)oxy]-1-pyrrolidinyl}-2-hydroxypropyl)oxy]-4-methylphenyl}-3-thiophenecarboxamide

20

APCI-MS: m/z 471.1 [M+H⁺]

Example 88

25 N-{2-[(3-{3-[(4-chlorophenyl)oxy]-1-pyrrolidinyl}-2-hydroxy-2-methylpropyl)oxy]phenyl}-2-thiophenecarboxamide, compound with trifluoroacetic acid

Aniline intermediate 3 (60 mg, 0.159 mmol), 2-thiophenecarboxylic acid (20.4 mg, 0.159 mmol) and HATU (72 mg, 0.191 mmol) were stirred in dichloromethane (2 ml).

30

Diisopropylethylamine was added to pH 8. The mixture was stirred overnight and then concentrated. The residue was purified on silica (dichloromethane/methanol 98/2) followed by purification on C18 (2 g Isolute, acetonitrile/water 20/80 to 35/65 with 0.5% trifluoroacetic acid) to give the title compound (75 mg, 79%).

5

$^1\text{H-NMR}$ (400 MHz, MeOD): δ 7.86 (m, 1H), 7.72 (m, 1H), 7.50 (m, 1H), 7.29 (m, 3H), 7.16 (m, 2H), 7.07 (m, 1H), 6.91 (m, 2H), 5.10 (m, 1H), 3.82-4.17 (m, 4H), 3.24-3.69 (m, 4H), 2.13-2.64 (m, 2H), 1.38 (m, 3H).

10

MS-APCI+: m/z 487 $[\text{MH}^+]$

Example 89

N-{2-[(3-{3-[(4-fluorophenyl)oxy]-1-pyrrolidinyl}-2-hydroxypropyl)oxy]-4-methylphenyl}-2-thiophenecarboxamide

15

APCI MS APCI-MS: m/z 471.1 $[\text{M}+\text{H}^+]$

Example 90

N-{2-[(3-{3-[(4-chlorophenyl)oxy]-1-pyrrolidinyl}-2-hydroxypropyl)oxy]phenyl}-2-furancarboxamide

20

APCI-MS: m/z 456.9 $[\text{M}+\text{H}^+]$

Example 91

N-{2-[(3-{3-[(4-chlorophenyl)oxy]-1-pyrrolidinyl}-2-hydroxypropyl)oxy]phenyl}-1-pyrrole-2-carboxamide

25

APCI-MS: m/z 456.1 $[\text{M}+\text{H}^+]$

30

Example 92

N-{2-[(3-{3-[(4-chlorophenyl)oxy]-1-pyrrolidinyl}-2-hydroxypropyl)oxy]-4-methylphenyl}-1H-pyrrole-3-carboxamide

APCI-MS: m/z 470.0 [M+H⁺]

5

Example 93

N-{2-[(3-{3-[(4-fluorophenyl)oxy]-1-pyrrolidinyl}-2-hydroxypropyl)oxy]-4-methylphenyl}-2-furancarboxamide

10 APCI-MS: m/z 455.1 [M+H⁺]

Example 94

N-{2-[(3-{3-[(4-chlorophenyl)oxy]-1-pyrrolidinyl}-2-hydroxy-2-methylpropyl)oxy]phenyl}cyclopentanecarboxamide, compound with
15 trifluoroacetic acid

The compound (80 mg, 86%) was prepared from aniline intermediate 3 (60 mg, 0.159 mmol) and cyclopentanecarboxylic acid (18 µl, 0.159 mmol) as described in Example 88.

20 ¹H-NMR (400 MHz, MeOD): δ 7.59 (m, 1H), 7.29 (m, 2H), 7.19 (m, 1H), 7.09 (m, 1H), 6.97 (m, 3H), 5.17 (m, 1H), 3.86-4.23 (m, 4H), 3.35-3.73 (m, 4H), 2.86 (m, 1H), 1.45 (bs, 3H).

MS-APCI+: m/z 473 [MH⁺]

25

Example 95

N-(2-{3-[3-(4-Fluoro-phenoxy)-pyrrolidin-1-yl]-2-hydroxy-2-methyl-propoxy}-phenyl)-benzamide

30 The compound was prepared using an analogous method as in Example 88.

APCI-MS: m/z 465 [MH⁺]

Example 96

5 N-(2-{3-[3-(4-Cyano-phenoxy)-pyrrolidin-1-yl]-2-hydroxy-2-methyl-propoxy}-phenyl)-benzamide

The compound was prepared using an analogous method as in Example 88.

10 APCI-MS: m/z 472 [MH⁺]

Example 97

N-(2-{3-[4-(3,4-Dichloro-phenoxy)-piperidin-1-yl]-2-hydroxy-2-methyl-propoxy}-phenyl)-benzamide

15

The compound was prepared using an analogous method as in Example 88.

APCI-MS: m/z 529 [MH⁺]

20 **Example 98**

N-(2-{3-[3-(4-Chloro-phenoxy)-pyrrolidin-1-yl]-2-hydroxy-2-methyl-propoxy}-phenyl)-benzamide

The compound was prepared using an analogous method as in Example 88.

25

APCI-MS: m/z 481 [MH⁺]

Example 99

30 N-(2-{3-[4-(3,4-Dichloro-phenylamino)-piperidin-1-yl]-2-hydroxy-2-methyl-propoxy}-phenyl)-benzamide

The compound was prepared using an analogous method as in Example 88.

APCI-MS: m/z 528 [MH⁺]

5

THP-1 Chemotaxis Assay

Introduction

The assay measured the chemotactic response elicited by MIP-1 α chemokine in the human monocytic cell line THP-1. The compounds of the Examples were evaluated by their
10 ability to depress the chemotactic response to a standard concentration of MIP-1 α chemokine.

Methods

Culture of THP-1 cells

15 Cells were thawed rapidly at 37°C from frozen aliquots and resuspended in a 25 cm flask containing 5 ml of RPMI-1640 medium supplemented with Glutamax and 10% heat inactivated fetal calf serum without antibiotics (RPMI+10%HIFCS). At day 3 the medium is discarded and replaced with fresh medium.

20 THP-1 cells are routinely cultured in RPMI-1640 medium supplemented with 10% heat inactivated fetal calf serum and glutamax but without antibiotics. Optimal growth of the cells requires that they are passaged every 3 days and that the minimum subculture density is 4x10⁵ cells/ml.

Chemotaxis assay

Cells were removed from the flask and washed by centrifugation in RPMI+10%HIFCS+glutamax. The cells were then resuspended at 2x10⁷ cells/ml in fresh medium (RPMI+10%HIFCS+glutamax) to which was added calcein-AM (5 μ l of stock solution to 1 ml to give a final concentration of 5x10⁻⁶M). After gentle mixing the
30 cells were incubated at 37°C in a CO₂ incubator for 30 minutes. The cells were then

diluted to 50 ml with medium and washed twice by centrifugation at 400xg. Labelled cells were then resuspended at a cell concentration of 1×10^7 cells/ml and incubated with an equal volume of MIP-1 α antagonist (10^{-10} M to 10^{-6} M final concentration) for 30 minutes at 37°C in a humidified CO₂ incubator.


5

Chemotaxis was performed using Neuroprobe 96-well chemotaxis plates employing 8 μ m filters (cat no. 101-8). Thirty microlitres of chemoattractant supplemented with various concentrations of antagonists or vehicle were added to the lower wells of the plate in triplicate. The filter was then carefully positioned on top and then 25 μ l of cells
10 preincubated with the corresponding concentration of antagonist or vehicle were added to the surface of the filter. The plate was then incubated for 2 hours at 37°C in a humidified CO₂ incubator. The cells remaining on the surface were then removed by adsorption and the whole plate was centrifuged at 2000 rpm for 10 minutes. The filter was then removed and the cells that had migrated to the lower wells were quantified by the fluorescence of
15 cell associated calcein-AM. Cell migration was then expressed in fluorescence units after subtraction of the reagent blank and values were standardized to % migration by comparing the fluorescence values with that of a known number of labelled cells. The effect of antagonists was calculated as % inhibition when the number of migrated cells were compared with vehicle.

20

CLAIMS

1. A compound of general formula



wherein:

m is 0, 1, 2 or 3;

each R¹ independently represents halogen, cyano, nitro, carboxyl, hydroxyl, C₃-C₆ cycloalkyl, C₁-C₆ alkoxy, C₁-C₆ alkoxycarbonyl, C₁-C₆ haloalkyl, C₁-C₆ haloalkoxy, -NR⁹R¹⁰, C₃-C₆ cycloalkylamino, C₁-C₆ alkylthio, C₁-C₆ alkylcarbonyl, C₁-C₆ alkylcarbonylamino, sulphonamido, C₁-C₆ alkylsulphonyl, -C(O)NR¹¹R¹², -NR¹³C(O)-(NH)_pR¹⁴, phenyl, or C₁-C₆ alkyl optionally substituted by carboxyl or C₁-C₆ alkoxycarbonyl;

p is 0 or 1;


X represents an oxygen atom or a CH₂, OCH₂, CH₂O, CH₂NH, NH, carbonyl or sulphonyl group and Y represents a nitrogen atom or a CH or C(OH) group, provided that when X represents an oxygen atom or a CH₂O, CH₂NH or NH group, then Y represents a CH group;

Z¹ represents a bond or a group (CH₂)_q where q is 1 or 2;

Z² represents a bond or a group CH₂, with the proviso that Z¹ and Z² do not both simultaneously represent a bond;

Q represents an oxygen or sulphur atom or a group CH₂ or NH;

R² represents a group



n is 0, 1 or 2;

each R³ independently represents a C₁-C₆ alkyl, C₁-C₆ alkoxycarbonyl, -CH₂OH or carboxyl group;

5 R⁴, R⁵, R⁶ and R⁷ each independently represent a hydrogen atom or a C₁-C₆ alkyl group, or R⁴, R⁵, R⁶ and R⁷ together represent a C₁-C₄ alkylene chain linking the two carbon atoms to which they are attached to form a 4- to 7-membered saturated carbocycle, or R⁵, R⁶ and R⁷ each represent a hydrogen atom and R⁴ and R⁸ together with the carbon atoms to which they are attached form a 5- to 6-membered saturated carbocycle;

10 R⁸ represents a hydrogen atom, a C₁-C₆ alkyl group or is linked to R⁴ as defined above;

R⁹ and R¹⁰ each independently represent a hydrogen atom or a C₁-C₆ alkyl group, or R⁹ and R¹⁰ together with the nitrogen atom to which they are attached form a 4- to 7-membered saturated heterocycle;

15 R¹¹ and R¹² each independently represent a hydrogen atom or a C₁-C₆ alkyl group optionally substituted by C₁-C₆ alkoxycarbonyl;

R¹³ represents a hydrogen atom or a C₁-C₆ alkyl group;

R¹⁴ represents a hydrogen atom, or a C₁-C₆ alkyl group optionally substituted by carboxyl, C₁-C₆ alkoxy or C₁-C₆ alkoxycarbonyl;

20 R¹⁵ represents a group C₂-C₆ alkyl, C₂-C₆ alkenyl, C₃-C₆ cycloalkyl, C₅-C₆ cycloalkenyl, adamantyl, phenyl or a saturated or unsaturated 5- to 10-membered heterocyclic ring system comprising at least one heteroatom selected from nitrogen, oxygen and sulphur, wherein each group may be optionally substituted by one or more substituents independently selected from nitro, hydroxyl, oxo, halogen, carboxyl, C₁-C₆ alkyl, C₁-C₆ alkoxy, C₁-C₆ alkylthio, C₁-C₆ alkylcarbonyl, C₁-C₆ alkoxycarbonyl, phenyl and -NHC(O)-R¹⁷, with the proviso that R¹⁵ does not represent an unsubstituted 1-pyrrolidinyl, an unsubstituted 1-piperidinyl or an unsubstituted 1-hexamethyleneiminyl group;

t is 0, 1, 2 or 3;

each R¹⁶ independently represents halogen, cyano, nitro, carboxyl, hydroxyl, C₃-C₆ cycloalkyl, C₁-C₆ alkoxy, C₁-C₆ alkoxycarbonyl, C₁-C₆ haloalkyl, C₁-C₆ haloalkoxy, -NR¹⁸R¹⁹, C₃-C₆ cycloalkylamino, C₁-C₆ alkylthio, C₁-C₆ alkylcarbonyl, C₁-C₆ alkylcarbonylamino, sulphonamido (-SO₂NH₂),
5 C₁-C₆ alkylsulphonyl, -C(O)NR²⁰R²¹, -NR²²C(O)(NH)_vR²³, phenyl, or C₁-C₆ alkyl optionally substituted by carboxyl or C₁-C₆ alkoxycarbonyl;

R¹⁷ represents a C₁-C₆ alkyl, amino or phenyl group;

R¹⁸ and R¹⁹ each independently represent a hydrogen atom or a C₁-C₆ alkyl group, or R¹⁸ and R¹⁹ together with the nitrogen atom to which they are attached form a 4- to 7-
10 membered saturated heterocycle;

R²⁰ and R²¹ each independently represent a hydrogen atom or a C₁-C₆ alkyl group optionally substituted by C₁-C₆ alkoxycarbonyl;

v is 0 or 1;

R²² represents a hydrogen atom or a C₁-C₆ alkyl group; and

15 R²³ represents a hydrogen atom, or a C₁-C₆ alkyl group optionally substituted by carboxyl, C₁-C₆ alkoxy or C₁-C₆ alkoxycarbonyl; or a pharmaceutically acceptable salt or solvate thereof.

2. A compound according to claim 1, wherein X represents an oxygen atom or a CH₂ or
20 NH group.

3. A compound according to claim 1, wherein Y represents a CH group.

4. A compound according to any one of claims 1 to 3, wherein Q represents an oxygen
25 atom.

5. A compound according to any one of claims 1 to 4, wherein R¹⁵ represents a group C₂-C₅ alkyl, C₂-C₄ alkenyl, C₃-C₆ cycloalkyl, C₅-C₆ cycloalkenyl, adamantyl, phenyl or a saturated or unsaturated 5- to 10-membered heterocyclic ring system comprising at
30 least one heteroatom selected from nitrogen, oxygen and sulphur, wherein each group may

be optionally substituted by one, two or three substituents independently selected from hydroxyl, oxo, halogen, carboxyl, C₁-C₆ alkyl, C₁-C₆ alkoxy, C₁-C₆ alkylthio, C₁-C₆ alkylcarbonyl, C₁-C₆ alkoxycarbonyl, phenyl and -NHC(O)-R¹⁷.

- 5 6. A compound according to claim 5, wherein the saturated or unsaturated 5- to 10-membered heterocyclic ring system comprising at least one heteroatom selected from nitrogen, oxygen and sulphur, is pyrrolidinyl, piperidinyl, pyrazolyl, thiazolidinyl, thienyl, thiadiazolyl, isoxazolyl, pyrrolyl, furanyl, thiazolyl, indolyl, quinolinyl, benzimidazolyl, triazolyl, tetrazolyl or pyridinyl.
- 10 7. A compound according to any one of claims 1 to 6, wherein each R¹⁶ independently represents halogen, cyano, C₁-C₄ alkoxy, C₁-C₄ alkoxycarbonyl, C₁-C₄ haloalkyl, C₁-C₄ alkylcarbonyl, phenyl or C₁-C₄ alkyl.
- 15 8. A compound of formula (I), or a pharmaceutically acceptable salt or solvate thereof, as defined in claim 1 being selected from:
- N-(5-Chloro-2-{3-[3-(4-chloro-phenoxy)-pyrrolidin-1-yl]-2-hydroxy-propoxy}-phenyl)-isobutyramide,
- Thiophene-2-carboxylic acid (2-{3-[3-(4-chloro-phenoxy)-pyrrolidin-1-yl]-2-hydroxy-propoxy}-phenyl)-amide,
- 20 N-[(2-{3-[3-(4-Chloro-phenoxy)-pyrrolidin-1-yl]-2-hydroxy-propoxy}-phenylcarbamoyl)-methyl]-benzamide,
- Pyrazine-2-carboxylic acid (2-{3-[3-(4-chloro-phenoxy)-pyrrolidin-1-yl]-2-hydroxy-propoxy}-phenyl)-amide,
- 25 Cyclohexanecarboxylic acid (2-{3-[3-(4-chloro-phenoxy)-pyrrolidin-1-yl]-2-hydroxy-propoxy}-phenyl)-amide,
- N-(2-{3-[3-(4-Chloro-phenoxy)-pyrrolidin-1-yl]-2-hydroxy-propoxy}-phenyl)-phthalamic acid methyl ester,
- N-(2-{3-[3-(4-Chloro-phenoxy)-pyrrolidin-1-yl]-2-hydroxy-propoxy}-phenyl)-3-
- 30 hydroxy-butyramide,

N-(2-{3-[3-(4-Chloro-phenoxy)-pyrrolidin-1-yl]-2-hydroxy-propoxy}-phenyl)-2-ureido-acetamide,

4-Acetylamino-N-(2-{3-[3-(4-chloro-phenoxy)-pyrrolidin-1-yl]-2-hydroxy-propoxy}-phenyl)-butyramide,

5 1-Acetyl-piperidine-4-carboxylic acid (2-{3-[3-(4-chloro-phenoxy)-pyrrolidin-1-yl]-2-hydroxy-propoxy}-phenyl)-amide,

N-(2-{3-[3-(4-Chloro-phenoxy)-pyrrolidin-1-yl]-2-hydroxy-propoxy}-phenyl)-3-methoxy-benzamide,

2-Acetylamino-N-(2-{3-[3-(4-chloro-phenoxy)-pyrrolidin-1-yl]-2-hydroxy-propoxy}-phenyl)-3-methyl-butyramide,

2-Acetylamino-N-(2-{3-[3-(4-chloro-phenoxy)-pyrrolidin-1-yl]-2-hydroxy-propoxy}-phenyl)-3-hydroxy-butyramide,

Adamantane-1-carboxylic acid (2-{3-[3-(4-chloro-phenoxy)-pyrrolidin-1-yl]-2-hydroxy-propoxy}-phenyl)-amide,

15 2-Acetylamino-N-(2-{3-[3-(4-chloro-phenoxy)-pyrrolidin-1-yl]-2-hydroxy-propoxy}-phenyl)-3-phenyl-propionamide,

N-(2-{3-[3-(4-Chloro-phenoxy)-pyrrolidin-1-yl]-2-hydroxy-propoxy}-phenyl)-2-methoxy-benzamide,

5-Methyl-thiophene-2-carboxylic acid (2-{3-[3-(4-chloro-phenoxy)-pyrrolidin-1-yl]-2-hydroxy-propoxy}-phenyl)-amide,

1-Acetyl-pyrrolidine-2-carboxylic acid (2-{3-[3-(4-chloro-phenoxy)-pyrrolidin-1-yl]-2-hydroxy-propoxy}-phenyl)-amide,

1,5-Dimethyl-1H-pyrazole-3-carboxylic acid (2-{3-[3-(4-chloro-phenoxy)-pyrrolidin-1-yl]-2-hydroxy-propoxy}-phenyl)-amide,

25 5-Oxo-pyrrolidine-2-carboxylic acid (2-{3-[3-(4-chloro-phenoxy)-pyrrolidin-1-yl]-2-hydroxy-propoxy}-phenyl)-amide,

1H-Indole-6-carboxylic acid (2-{3-[3-(4-chloro-phenoxy)-pyrrolidin-1-yl]-2-hydroxy-propoxy}-phenyl)-amide,

Cyclobutanecarboxylic acid (2-{3-[3-(4-chloro-phenoxy)-pyrrolidin-1-yl]-2-hydroxy-propoxy}-phenyl)-amide,

N-(2-{3-[3-(4-Chloro-phenoxy)-pyrrolidin-1-yl]-2-hydroxy-propoxy}-phenyl)-propionamide,

Pentanoic acid (2-{3-[3-(4-chloro-phenoxy)-pyrrolidin-1-yl]-2-hydroxy-propoxy}-phenyl)-amide,

5 Pent-4-enoic acid (2-{3-[3-(4-chloro-phenoxy)-pyrrolidin-1-yl]-2-hydroxy-propoxy}-phenyl)-amide,

Cyclopentanecarboxylic acid (2-{3-[3-(4-chloro-phenoxy)-pyrrolidin-1-yl]-2-hydroxy-propoxy}-phenyl)-amide,

10 Cyclopropanecarboxylic acid (2-{3-[3-(4-chloro-phenoxy)-pyrrolidin-1-yl]-2-hydroxy-propoxy}-phenyl)-amide,

N-(2-{3-[3-(4-Chloro-phenoxy)-pyrrolidin-1-yl]-2-hydroxy-propoxy}-phenyl)-isobutyramide,

N-(2-{3-[3-(4-Chloro-phenoxy)-pyrrolidin-1-yl]-2-hydroxy-propoxy}-phenyl)-2-methylsulfanyl-acetamide,

15 2-Acetylamino-N-(2-{3-[3-(4-chloro-phenoxy)-pyrrolidin-1-yl]-2-hydroxy-propoxy}-phenyl)-propionamide,

N-(2-{3-[3-(4-Chloro-phenoxy)-pyrrolidin-1-yl]-2-hydroxy-propoxy}-phenyl)-butyramide,

20 N-(2-{3-[3-(4-Chloro-phenoxy)-pyrrolidin-1-yl]-2-hydroxy-propoxy}-phenyl)-3-methyl-butylamide,

N-(2-{3-[3-(4-Chloro-phenoxy)-pyrrolidin-1-yl]-2-hydroxy-propoxy}-phenyl)-2-methoxy-acetamide,

N-(2-{3-[3-(4-Chloro-phenoxy)-pyrrolidin-1-yl]-2-hydroxy-propoxy}-phenyl)-2,2-dimethyl-propionamide,

25 5-Oxo-hexanoic acid (2-{3-[3-(4-chloro-phenoxy)-pyrrolidin-1-yl]-2-hydroxy-propoxy}-phenyl)-amide,

Hexanoic acid (2-{3-[3-(4-chloro-phenoxy)-pyrrolidin-1-yl]-2-hydroxy-propoxy}-phenyl)-amide,

30 2-Chloro-N-(2-{3-[3-(4-chloro-phenoxy)-pyrrolidin-1-yl]-2-hydroxy-propoxy}-phenyl)-benzamide,

3-Chloro-N-(2-{3-[3-(4-chloro-phenoxy)-pyrrolidin-1-yl]-2-hydroxy-propoxy}-phenyl)-benzamide,

(4R)-N-(2-{3-[3-(4-chlorophenoxy)-1-pyrrolidinyl]-2-hydroxypropoxy}phenyl)-1,3-thiazolidine-4-carboxamide ditrifluoroacetate,

5 Thiophene-2-carboxylic acid (2-{3-[4-(3,4-dichloro-phenoxy)-piperidin-1-yl]-2-hydroxy-propoxy}-phenyl)-amide,

N-(2-{3-[4-(3,4-Dichloro-phenoxy)-piperidin-1-yl]-2-hydroxy-propoxy}-phenyl)-benzamide,

10 N-(2-{3-[4-(3,4-Dichloro-phenoxy)-piperidin-1-yl]-2-hydroxy-propoxy}-phenyl)-nicotinamide,

Pyridine-2-carboxylic acid (2-{3-[4-(3,4-dichloro-phenoxy)-piperidin-1-yl]-2-hydroxy-propoxy}-phenyl)-amide,

N-(2-{3-[4-(3,4-Dichloro-phenoxy)-piperidin-1-yl]-2-hydroxy-propoxy}-phenyl)-isonicotinamide,

15 Cyclohexanecarboxylic acid (2-{3-[4-(3,4-dichloro-phenoxy)-piperidin-1-yl]-2-hydroxy-propoxy}-phenyl)-amide,

N-(2-{3-[4-(3,4-Dichloro-phenoxy)-piperidin-1-yl]-2-hydroxy-propoxy}-phenyl)-3-hydroxy-butyramide,

20 5-Methyl-thiophene-2-carboxylic acid (2-{3-[4-(3,4-dichloro-phenoxy)-piperidin-1-yl]-2-hydroxy-propoxy}-phenyl)-amide,

Cyclobutanecarboxylic acid (2-{3-[4-(3,4-dichloro-phenoxy)-piperidin-1-yl]-2-hydroxy-propoxy}-phenyl)-amide,

N-(2-{3-[4-(3,4-Dichloro-phenoxy)-piperidin-1-yl]-2-hydroxy-propoxy}-phenyl)-propionamide,

25 Pentanoic acid (2-{3-[4-(3,4-dichloro-phenoxy)-piperidin-1-yl]-2-hydroxy-propoxy}-phenyl)-amide,

Pent-4-enoic acid (2-{3-[4-(3,4-dichloro-phenoxy)-piperidin-1-yl]-2-hydroxy-propoxy}-phenyl)-amide,

30 Cyclopentanecarboxylic acid (2-{3-[4-(3,4-dichloro-phenoxy)-piperidin-1-yl]-2-hydroxy-propoxy}-phenyl)-amide,

N-(2-{3-[4-(3,4-Dichloro-phenoxy)-piperidin-1-yl]-2-hydroxy-propoxy}-phenyl)-3-methyl-butyramide,

N-(2-{3-[3-(4-chlorophenoxy)-1-pyrrolidinyl]-2-hydroxypropoxy}phenyl)-2,2,2-trifluoroacetamide hydrochloride,

5 4-(2-{3-[4-(3,4-Dichloro-phenoxy)-piperidin-1-yl]-2-hydroxy-propoxy}-phenylcarbamoyl)-3-methyl-butyric acid,

N-(2-{3-[4-(3,4-Dichloro-phenoxy)-piperidin-1-yl]-2-hydroxy-propoxy}-phenyl)-succinamic acid,

10 Furan-2-carboxylic acid (2-{3-[3-(4-chloro-phenoxy)-pyrrolidin-1-yl]-2-hydroxy-propoxy}-4-methyl-phenyl)-amide,

1H-Pyrrole-2-carboxylic acid (2-{3-[3-(4-chloro-phenoxy)-pyrrolidin-1-yl]-2-hydroxy-propoxy}-4-methyl-phenyl)-amide,

Thiophene-2-carboxylic acid (2-{3-[3-(4-chloro-phenoxy)-pyrrolidin-1-yl]-2-hydroxy-propoxy}-4-methyl-phenyl)-amide,

15 Cyclopentanecarboxylic acid (2-{3-[3-(4-chloro-phenoxy)-pyrrolidin-1-yl]-2-hydroxy-propoxy}-4-methyl-phenyl)-amide,

5-Methyl-thiophene-2-carboxylic acid (2-{3-[3-(4-chloro-phenoxy)-pyrrolidin-1-yl]-2-hydroxy-propoxy}-4-methyl-phenyl)-amide,

20 3-Chloro-thiophene-2-carboxylic acid (2-{3-[3-(4-chloro-phenoxy)-pyrrolidin-1-yl]-2-hydroxy-propoxy}-4-methyl-phenyl)-amide,

5-Methyl-isoxazole-4-carboxylic acid (2-{3-[3-(4-chloro-phenoxy)-pyrrolidin-1-yl]-2-hydroxy-propoxy}-4-methyl-phenyl)-amide,

[1,2,3]Thiadiazole-4-carboxylic acid (2-{3-[3-(4-chloro-phenoxy)-pyrrolidin-1-yl]-2-hydroxy-propoxy}-4-methyl-phenyl)-amide,

25 3-Methyl-furan-2-carboxylic acid (2-{3-[3-(4-chloro-phenoxy)-pyrrolidin-1-yl]-2-hydroxy-propoxy}-4-methyl-phenyl)-amide,

Cyclopent-1-enecarboxylic acid (2-{3-[3-(4-chloro-phenoxy)-pyrrolidin-1-yl]-2-hydroxy-propoxy}-4-methyl-phenyl)-amide,

30 2-Methyl-furan-3-carboxylic acid (2-{3-[3-(4-chloro-phenoxy)-pyrrolidin-1-yl]-2-hydroxy-propoxy}-4-methyl-phenyl)-amide,

3-Methyl-thiophene-2-carboxylic acid (2-{3-[3-(4-chloro-phenoxy)-pyrrolidin-1-yl]-2-hydroxy-propoxy}-4-methyl-phenyl)-amide,

5-Nitro-1H-pyrazole-3-carboxylic acid (2-{3-[3-(4-chloro-phenoxy)-pyrrolidin-1-yl]-2-hydroxy-propoxy}-4-methyl-phenyl)-amide,

5 Thiophene-3-carboxylic acid (2-{3-[3-(4-chloro-phenoxy)-pyrrolidin-1-yl]-2-hydroxy-propoxy}-4-methyl-phenyl)-amide,

Cyclobutanecarboxylic acid (2-{3-[3-(4-chloro-phenoxy)-pyrrolidin-1-yl]-2-hydroxy-propoxy}-4-methyl-phenyl)-amide,

10 Furan-2-carboxylic acid (2-{3-[3-(4-fluoro-phenoxy)-pyrrolidin-1-yl]-2-hydroxy-propoxy}-4-methyl-phenyl)-amide,

1H-Pyrrole-2-carboxylic acid (2-{3-[3-(4-fluoro-phenoxy)-pyrrolidin-1-yl]-2-hydroxy-propoxy}-4-methyl-phenyl)-amide,

Thiophene-2-carboxylic acid (2-{3-[3-(4-fluoro-phenoxy)-pyrrolidin-1-yl]-2-hydroxy-propoxy}-4-methyl-phenyl)-amide,

15 3-Chloro-thiophene-2-carboxylic acid (2-{3-[3-(4-fluoro-phenoxy)-pyrrolidin-1-yl]-2-hydroxy-propoxy}-4-methyl-phenyl)-amide,

5-Methyl-isoxazole-4-carboxylic acid (2-{3-[3-(4-fluoro-phenoxy)-pyrrolidin-1-yl]-2-hydroxy-propoxy}-4-methyl-phenyl)-amide,

20 3-Methyl-furan-2-carboxylic acid (2-{3-[3-(4-fluoro-phenoxy)-pyrrolidin-1-yl]-2-hydroxy-propoxy}-4-methyl-phenyl)-amide,

Cyclopent-1-enecarboxylic acid (2-{3-[3-(4-fluoro-phenoxy)-pyrrolidin-1-yl]-2-hydroxy-propoxy}-4-methyl-phenyl)-amide,

2-Methyl-furan-3-carboxylic acid (2-{3-[3-(4-fluoro-phenoxy)-pyrrolidin-1-yl]-2-hydroxy-propoxy}-4-methyl-phenyl)-amide,

25 3-Methyl-thiophene-2-carboxylic acid (2-{3-[3-(4-fluoro-phenoxy)-pyrrolidin-1-yl]-2-hydroxy-propoxy}-4-methyl-phenyl)-amide,

5-Chloro-thiophene-2-carboxylic acid (2-{3-[3-(4-fluoro-phenoxy)-pyrrolidin-1-yl]-2-hydroxy-propoxy}-4-methyl-phenyl)-amide,

30 Thiophene-3-carboxylic acid (2-{3-[3-(4-fluoro-phenoxy)-pyrrolidin-1-yl]-2-hydroxy-propoxy}-4-methyl-phenyl)-amide,

2,5-Dimethyl-furan-3-carboxylic acid (2-{3-[3-(4-fluoro-phenoxy)-pyrrolidin-1-yl]-2-hydroxy-propoxy}-4-methyl-phenyl)-amide,

Cyclobutanecarboxylic acid (2-{3-[3-(4-fluoro-phenoxy)-pyrrolidin-1-yl]-2-hydroxy-propoxy}-4-methyl-phenyl)-amide,

5 Furan-3-carboxylic acid (2-{3-[3-(4-fluoro-phenoxy)-pyrrolidin-1-yl]-2-hydroxy-propoxy}-4-methyl-phenyl)-amide,

N-{2-[(3-{3-[(4-fluorophenyl)oxy]-1-pyrrolidinyl}-2-hydroxypropyl)oxy]-4-methylphenyl}-1H-pyrrole-2-carboxamide,

10 N-{2-[(3-{3-[(4-chlorophenyl)oxy]-1-pyrrolidinyl}-2-hydroxypropyl)oxy]-4-methylphenyl}-3-thiophenecarboxamide,

N-{2-[(3-{3-[(4-chlorophenyl)oxy]-1-pyrrolidinyl}-2-hydroxy-2-methylpropyl)oxy]phenyl}-2-thiophenecarboxamide, compound with trifluoroacetic acid,

N-{2-[(3-{3-[(4-fluorophenyl)oxy]-1-pyrrolidinyl}-2-hydroxypropyl)oxy]-4-methylphenyl}-2-thiophenecarboxamide,

15 N-{2-[(3-{3-[(4-chlorophenyl)oxy]-1-pyrrolidinyl}-2-hydroxypropyl)oxy]phenyl}-2-furancarboxamide,

N-{2-[(3-{3-[(4-chlorophenyl)oxy]-1-pyrrolidinyl}-2-hydroxypropyl)oxy]phenyl}-1-pyrrole-2-carboxamide

20 N-{2-[(3-{3-[(4-chlorophenyl)oxy]-1-pyrrolidinyl}-2-hydroxypropyl)oxy]-4-methylphenyl}-1H-pyrrole-3-carboxamide,

N-{2-[(3-{3-[(4-fluorophenyl)oxy]-1-pyrrolidinyl}-2-hydroxypropyl)oxy]-4-methylphenyl}-2-furancarboxamide,

25 N-{2-[(3-{3-[(4-chlorophenyl)oxy]-1-pyrrolidinyl}-2-hydroxy-2-methylpropyl)oxy]phenyl}cyclopentanecarboxamide, compound with trifluoroacetic acid,

N-(2-{3-[3-(4-Fluoro-phenoxy)-pyrrolidin-1-yl]-2-hydroxy-2-methyl-propoxy}-phenyl)-benzamide,


N-(2-{3-[3-(4-Cyano-phenoxy)-pyrrolidin-1-yl]-2-hydroxy-2-methyl-propoxy}-phenyl)-benzamide,

N-(2-{3-[4-(3,4-Dichloro-phenoxy)-piperidin-1-yl]-2-hydroxy-2-methyl-propoxy}-phenyl)-benzamide,

N-(2-{3-[3-(4-Chloro-phenoxy)-pyrrolidin-1-yl]-2-hydroxy-2-methyl-propoxy}-phenyl)-benzamide, and

N-(2-{3-[4-(3,4-Dichloro-phenylamino)-piperidin-1-yl]-2-hydroxy-2-methyl-propoxy}-phenyl)-benzamide.

9. A process for the preparation of a compound of formula (I) as defined in claim 1 which comprises reacting a compound of general formula



or a salt thereof, wherein m, n, t, R¹, R³, R⁴, R⁵, R⁶, R⁷, R⁸, R¹⁶, Q, Z¹ and Z² are as defined in formula (I), with a compound of general formula



or chemically equivalent derivative thereof, wherein R¹⁵ is as defined in formula (I); and optionally thereafter forming a pharmaceutically acceptable salt or solvate of the compound of formula (I) obtained.

10. A pharmaceutical composition comprising a compound of formula (I), or a pharmaceutically acceptable salt or solvate thereof, as claimed in any one of claims 1 to 8 in association with a pharmaceutically acceptable adjuvant, diluent or carrier.

11. A process for the preparation of a pharmaceutical composition as claimed in claim 10 which comprises mixing a compound of formula (I), or a pharmaceutically acceptable salt or solvate thereof, as claimed in any one of claims 1 to 8 with a pharmaceutically acceptable adjuvant, diluent or carrier.

12. A compound of formula (I), or a pharmaceutically-acceptable salt or solvate thereof, as claimed in any one of claims 1 to 8 for use in therapy.

5 13. Use of a compound of formula (I), or a pharmaceutically acceptable salt or solvate thereof, as claimed in any one of claims 1 to 8 in the manufacture of a medicament for use in therapy.

14. Use of a compound of formula (I); or a pharmaceutically acceptable salt or solvate
10 thereof, as claimed in any one of claims 1 to 8 in the manufacture of a medicament for the treatment of human diseases or conditions in which modulation of chemokine receptor activity is beneficial.

15. Use of a compound of formula (I), or a pharmaceutically acceptable salt or solvate
15 thereof, as claimed in any one of claims 1 to 8 in the manufacture of a medicament for use in treating rheumatoid arthritis.

16. Use of a compound of formula (I), or a pharmaceutically acceptable salt or solvate
thereof, as claimed in any one of claims 1 to 8 in the manufacture of a medicament for use
20 in treating chronic obstructive pulmonary disease.

17. Use of a compound of formula (I), or a pharmaceutically acceptable salt or solvate
thereof, as claimed in any one of claims 1 to 8 in the manufacture of a medicament for use
in treating asthma.

25 18. Use of a compound of formula (I), or a pharmaceutically acceptable salt or solvate thereof, as claimed in any one of claims 1 to 8 in the manufacture of a medicament for use in treating multiple sclerosis.

19. A method of treating an inflammatory disease in a patient suffering from, or at risk of, said disease, which comprises administering to the patient a therapeutically effective amount of a compound of formula (I), or a pharmaceutically acceptable salt or solvate thereof, as claimed in any one of claims 1 to 8.

5

20. A method of treating an airways disease in a patient suffering from, or at risk of, said disease, which comprises administering to the patient a therapeutically effective amount of a compound of formula (I), or a pharmaceutically acceptable salt or solvate thereof, as claimed in any one of claims 1 to 8.

10

INTERNATIONAL SEARCH REPORT

International application No.

PCT/SE 01/01378

A. CLASSIFICATION OF SUBJECT MATTER

IPC7: C07D 211/46, C07D 211/58, C07D 211/22, C07D 207/12, C07D 295/08,
C07D 295/10, A61K 31/295

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC7: C07D

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

SE,DK,FI,NO classes as above

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	WO 0035449 A1 (DU PONT PHARMACEUTICALS COMPANY), 22 June 2000 (22.06.00)	1-18

A	WO 0035451 A1 (DU PONT PHARMACEUTICALS COMPANY), 22 June 2000 (22.06.00)	1-18

☐ Further documents are listed in the continuation of Box C.☒ See patent family annex.

* Special categories of cited documents:

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier application or patent but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance: the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance: the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

"&" document member of the same patent family

Date of the actual completion of the international search

Date of mailing of the international search report

9 November 2001

14 -11- 2001

Name and mailing address of the ISA/
Swedish Patent Office
Box 5055, S-102 42 STOCKHOLM
Facsimile No. +46 8 666 02 86

Authorized officer

Göran Karlsson/BS
Telephone No. +46 8 782 25 00

INTERNATIONAL SEARCH REPORT

International application No.
PCT/SE01/01378

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.: 19-20
because they relate to subject matter not required to be searched by this Authority, namely:
**A method for treatment of the human or animal body by therapy,
see rule 39.1**
2. ☐ Claims Nos.:
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
☐ No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT
Information on patent family members

International application No.

PCT/SE 01/01378

Patent document cited in search report			Publication date	Patent family member(s)		Publication date
WO	0035449	A1	22/06/00	AU	1940600 A	03/07/00
				AU	2057200 A	03/07/00
				AU	2482100 A	03/07/00
				AU	3126600 A	03/07/00
				AU	3126700 A	03/07/00
				AU	4820699 A	01/02/00
				BR	9911920 A	27/03/01
				EP	1099266 A	16/05/01
				NO	20010071 A	08/03/01
				NO	20012977 A	20/08/01
				US	6087034 A	11/07/00
				WO	0003445 A	20/01/00
				WO	0035451 A	22/06/00
				WO	0035452 A	22/06/00
				WO	0035453 A	22/06/00
				WO	0035454 A	22/06/00
				AU	3634001 A	08/05/01
				WO	0130752 A	03/05/01
WO	0035451	A1	22/06/00	AU	1940600 A	03/07/00
				AU	2057200 A	03/07/00
				AU	2482100 A	03/07/00
				AU	3126600 A	03/07/00
				AU	3126700 A	03/07/00
				AU	4820699 A	01/02/00
				BR	9911920 A	27/03/01
				EP	1099266 A	16/05/01
				NO	20010071 A	08/03/01
				NO	20012977 A	20/08/01
				US	6087034 A	11/07/00
				WO	0003445 A	20/01/00
				WO	0035449 A	22/06/00
				WO	0035452 A	22/06/00
				WO	0035453 A	22/06/00
				WO	0035454 A	22/06/00